Identification

Name
Imipramine
Accession Number
DB00458  (APRD00672, DB08002)
Type
Small Molecule
Groups
Approved
Description

Imipramine, the prototypical tricyclic antidepressant (TCA), is a dibenzazepine-derivative TCA. TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, imipramine does not affect mood or arousal, but may cause sedation. In depressed individuals, imipramine exerts a positive effect on mood. TCAs are potent inhibitors of serotonin and norepinephrine reuptake. Tertiary amine TCAs, such as imipramine and amitriptyline, are more potent inhibitors of serotonin reuptake than secondary amine TCAs, such as nortriptyline and desipramine. TCAs also down-regulate cerebral cortical β-adrenergic receptors and sensitize post-synaptic serotonergic receptors with chronic use. The antidepressant effects of TCAs are thought to be due to an overall increase in serotonergic neurotransmission. TCAs also block histamine H1 receptors, α1-adrenergic receptors and muscarinic receptors, which accounts for their sedative, hypotensive and anticholinergic effects (e.g. blurred vision, dry mouth, constipation, urinary retention), respectively. Imipramine has less sedative and anticholinergic effects than the tertiary amine TCAs, amitriptyline and clomipramine. See toxicity section below for a complete listing of side effects. Imipramine may be used to treat depression and nocturnal enuresis in children. Unlabeled indications include chronic and neuropathic pain (including diabetic neuropathy), panic disorder, attention-deficit/hyperactivity disorder (ADHD), and post-traumatic stress disorder (PTSD).

Structure
Thumb
Synonyms
  • 10,11-dihydro-N,N-Dimethyl-5H-dibenz[b,F]azepine-5-propanamine
  • 3-(5H-DIBENZO[b,F]azepin-5-yl)-N,N-dimethylpropan-1-amine
  • 5-[3-(dimethylamino)Propyl]-10,11-dihydro-5H-dibenz[b,F]azepine
  • Antideprin
  • Imipramin
  • Imipramine
  • Imipraminum
  • Imizine
  • Irmin
  • Melipramine
  • N-(gamma-Dimethylaminopropyl)iminodibenzyl
  • N-(γ-dimethylaminopropyl)iminodibenzyl
External IDs
NSC-169866 / ORG-2463
Product Ingredients
IngredientUNIICASInChI Key
Imipramine HydrochlorideBKE5Q1J60U113-52-0XZZXIYZZBJDEEP-UHFFFAOYSA-N
Imipramine PamoateMC34P3029810075-24-8SBDXQUVAAJKLDH-UHFFFAOYSA-N
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
ImipramineTablet75 mgOralAa Pharma Inc1989-12-31Not applicableCanada
ImipramineTablet50 mgOralAa Pharma Inc1975-12-31Not applicableCanada
ImipramineTablet25 mgOralAa Pharma Inc1975-12-31Not applicableCanada
ImipramineTablet10 mgOralAa Pharma Inc1976-12-31Not applicableCanada
Imipramine 10tabTablet10 mgOralPro Doc Limitee1976-12-312010-07-13Canada
Imipramine 25tabTablet25 mgOralPro Doc Limitee1976-12-312010-07-13Canada
Imipramine 50 Tab 50mgTablet50 mgOralPro Doc Limitee1978-12-312010-07-13Canada
Imipramine Hydrochloride Tablets 25mgTablet25 mgOralD.C. Labs Limited1977-12-312003-07-11Canada
Imipramine Hydrochloride Tablets 50mgTablet50 mgOralD.C. Labs Limited1977-12-312003-07-11Canada
Imipramine PamoateCapsule100 mg/1OralMallinckrodt2009-10-152016-12-31Us00406 9932 03 nlmimage10 313d98bc
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-imipramineTablet25 mgOralApotex CorporationNot applicableNot applicableCanada
Apo-imipramineTablet75 mgOralApotex CorporationNot applicableNot applicableCanada
Apo-imipramineTablet10 mgOralApotex CorporationNot applicableNot applicableCanada
Apo-imipramineTablet50 mgOralApotex CorporationNot applicableNot applicableCanada
Imipramine HydrochlorideTablet50 mg/1OralLake Erie Medical &Surgical Supply Dba Quality Care Products Llc1983-10-21Not applicableUs
Imipramine HydrochlorideTablet, film coated50 mg/1Oralbryant ranch prepack1990-06-05Not applicableUs
Imipramine HydrochlorideTablet, film coated25 mg/1OralRemedy Repack2016-11-17Not applicableUs
Imipramine HydrochlorideTablet, film coated50 mg/1OralPhysicians Total Care, Inc.1992-11-12Not applicableUs
Imipramine HydrochlorideTablet, film coated25 mg/1OralA S Medication Solutions1990-06-052017-06-20Us
Imipramine HydrochlorideTablet10 mg/1OralKaiser Foundations Hospitals2012-05-31Not applicableUs
International/Other Brands
Antidep (Torrent) / Depsonil (Abbott) / Depsonil-PM (Abbott) / Elamin (Baroda) / Fronil (Johnson) / Imidol (Tanabe Mitsubishi Pharma) / Imipramin Dak (Nycomed) / Imiprex (Dumex) / Pramin (Incepta)
Categories
UNII
OGG85SX4E4
CAS number
50-49-7
Weight
Average: 280.4073
Monoisotopic: 280.193948778
Chemical Formula
C19H24N2
InChI Key
BCGWQEUPMDMJNV-UHFFFAOYSA-N
InChI
InChI=1S/C19H24N2/c1-20(2)14-7-15-21-18-10-5-3-8-16(18)12-13-17-9-4-6-11-19(17)21/h3-6,8-11H,7,12-15H2,1-2H3
IUPAC Name
(3-{2-azatricyclo[9.4.0.0³,⁸]pentadeca-1(15),3,5,7,11,13-hexaen-2-yl}propyl)dimethylamine
SMILES
CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C12

Pharmacology

Indication

For the relief of symptoms of depression and as temporary adjunctive therapy in reducing enuresis in children aged 6 years and older. May also be used to manage panic disorders, with or without agoraphobia, as a second line agent in ADHD, management of eating disorders, for short-term management of acute depressive episodes in bipolar disorder and schizophrenia, and for symptomatic treatment of postherpetic neuralgia.

Structured Indications
Pharmacodynamics

Imipramine is a tricyclic antidepressant with general pharmacological properties similar to those of structurally related tricyclic antidepressant drugs such as amitriptyline and doxepin. A tertiary amine, imipramine inhibits the reuptake of serotonin more so than most secondary amine tricyclics, meaning that it blocks the reuptake of neurotransmitters serotonin and noradrenaline almost equally. With chronic use, imipramine also down-regulates cerebral cortical β-adrenergic receptors and sensitizes post-synaptic sertonergic receptors, which also contributes to increased serotonergic transmission. It takes approximately 2 - 4 weeks for antidepressants effects to occur. The onset of action may be longer, up to 8 weeks, in some individuals. It is also effective in migraine prophylaxis, but not in abortion of acute migraine attack.

Mechanism of action

Imipramine works by inhibiting the neuronal reuptake of the neurotransmitters norepinephrine and serotonin. It binds the sodium-dependent serotonin transporter and sodium-dependent norepinephrine transporter preventing or reducing the reuptake of norepinephrine and serotonin by nerve cells. Depression has been linked to a lack of stimulation of the post-synaptic neuron by norepinephrine and serotonin. Slowing the reuptake of these neurotransmitters increases their concentration in the synaptic cleft, which is thought to contribute to relieving symptoms of depression. In addition to acutely inhibiting neurotransmitter re-uptake, imipramine causes down-regulation of cerebral cortical beta-adrenergic receptors and sensitization of post-synaptic serotonergic receptors with chronic use. This leads to enhanced serotonergic transmission.

TargetActionsOrganism
ASodium-dependent noradrenaline transporter
inhibitor
Human
ASodium-dependent serotonin transporter
inhibitor
Human
U5-hydroxytryptamine receptor 2A
antagonist
Human
NHistamine H1 receptor
antagonist
Human
NAlpha-1A adrenergic receptor
antagonist
Human
NAlpha-1D adrenergic receptor
antagonist
Human
NMuscarinic acetylcholine receptor M1
antagonist
Human
NMuscarinic acetylcholine receptor M2
antagonist
Human
NMuscarinic acetylcholine receptor M3
antagonist
Human
NMuscarinic acetylcholine receptor M4
antagonist
Human
NMuscarinic acetylcholine receptor M5
antagonist
Human
NPotassium voltage-gated channel subfamily D member 2
inhibitor
Human
NPotassium voltage-gated channel subfamily D member 3
inhibitor
Human
U5-hydroxytryptamine receptor 2C
antagonist
binder
Human
UAlpha-1B adrenergic receptor
antagonist
Human
U5-hydroxytryptamine receptor 7
antagonist
Human
UD(1) dopamine receptor
binder
Human
UD(2) dopamine receptor
binder
Human
UPotassium voltage-gated channel subfamily H member 2
inhibitor
Human
USodium-dependent dopamine transporterNot AvailableHuman
U5-hydroxytryptamine receptor 1A
activator
Human
U5-hydroxytryptamine receptor 6
binder
Human
UPotassium voltage-gated channel subfamily H member 1Not AvailableHuman
UAlpha-1-acid glycoprotein 2Not AvailableHuman
Absorption

Rapidly and well absorbed after oral administration. Bioavailability is approximately 43%. Peak plasma concentrations usually attained 1 - 2 hours following oral administration. Absorption is unaffected by food.

Volume of distribution
Not Available
Protein binding

60-95%

Metabolism

Exclusively metabolized by the liver. Imipramine is converted in the liver by various CYP isoenzymes (e.g. CYP1A2, CYP2D6, CYP3A4, CYP2C9) to active metabolites desipramine and 2-hydroxydesipramine.

Route of elimination

Approximately 40% of an orally administered dose is eliminated in urine within 24 hours, 70% in 72 hours. Small amounts are eliminated in feces via the biliary elimination.

Half life

Imipramine - 8-20 hours; Desipramine (active metabolite) - up to 125 hours

Clearance
Not Available
Toxicity

Oral, rat LD50: 355 to 682 mg/kg. Toxic signs proceed progressively from depression, irregular respiration and ataxia to convulsions and death. Antagonism of the histamine H1 and α1 receptors can lead to sedation and hypotension. Antimuscarinic and anticholinergic side effects such as blurred vision, dry mouth, constipation and urine retention may occur. Cardiotoxicity may occur with high doses of imipramine. Cardiovascular side effects in postural hypotension, tachycardia, hypertension, ECG changes and congestive heart failure. Psychotoxic effects include impaired memory and delirium. Induction of hypomanic or manic episodes may occur in patients with a history of bipolar disorder. Withdrawal symptoms include GI disturbances (e.g. nausea, vomiting, abdominal pain, diarrhea), anxiety, insomnia, nervousness, headache and malaise.

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Imipramine Action PathwayDrug action
Imipramine Metabolism PathwayDrug metabolism
Pharmacogenomic Effects/ADRs
Interacting Gene/EnzymeAllele nameGenotype(s)Defining Change(s)Type(s)DescriptionDetails
Cytochrome P450 2D6CYP2D6*4(A;A)A AlleleEffect Directly StudiedPatients with this genotype have reduced metabolism of imipramine.Details
Cytochrome P450 2D6CYP2D6*3Not Available2549delAEffect Directly StudiedThe presence of this polymorphism in CYP2D6 is associated with poor metabolism of imipramine.Details
Cytochrome P450 2D6CYP2D6*4Not AvailableA alleleEffect Directly StudiedThe presence of this polymorphism in CYP2D6 is associated with poor metabolism of imipramine.Details
Cytochrome P450 2D6CYP2D6*5Not AvailableWhole-gene deletionEffect Directly StudiedThe presence of this polymorphism in CYP2D6 is associated with poor metabolism of imipramine.Details
Cytochrome P450 2D6CYP2D6*6Not Available1707delTEffect Directly StudiedThe presence of this polymorphism in CYP2D6 is associated with poor metabolism of imipramine.Details
Cytochrome P450 2C19CYP2C19*2Not Available681G>AEffect Directly StudiedThe presence of this polymorphism in CYP2C19 is associated with poor metabolism of imipramine.Details
Cytochrome P450 2C19CYP2C19*3Not Available636G>AEffect Directly StudiedThe presence of this polymorphism in CYP2C19 is associated with reduced or poor metabolism of imipramine.Details
Cytochrome P450 2D6CYP2D6*7Not Available2935A>CEffect InferredPoor drug metabolizer. For individual with two non-functional alleles, dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*8Not Available1758G>TEffect InferredPoor drug metabolizer. For individual with two non-functional alleles, dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*11Not Available883G>CEffect InferredPoor drug metabolizer. For individual with two non-functional alleles, dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*12Not Available124G>AEffect InferredPoor drug metabolizer. For individual with two non-functional alleles, dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*13Not AvailableCYP2D7/2D6 hybrid gene structureEffect InferredPoor drug metabolizer. For individual with two non-functional alleles, dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*14ANot Available1758G>AEffect InferredPoor drug metabolizer. For individual with two non-functional alleles, dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*15Not Available137insT, 137_138insTEffect InferredPoor drug metabolizer. For individual with two non-functional alleles, dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*19Not Available2539_2542delAACTEffect InferredPoor drug metabolizer. For individual with two non-functional alleles, dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*20Not Available1973_1974insGEffect InferredPoor drug metabolizer. For individual with two non-functional alleles, dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*21Not Available2573insCEffect InferredPoor drug metabolizer. For individual with two non-functional alleles, dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*31Not Available-1770G>A / -1584C>G  … show all Effect InferredPoor drug metabolizer. For individual with two non-functional alleles, dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*36Not Available100C>T / -1426C>T  … show all Effect InferredPoor drug metabolizer. For individual with two non-functional alleles, dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*38Not Available2587_2590delGACTEffect InferredPoor drug metabolizer. For individual with two non-functional alleles, dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*40Not Available1863_1864ins(TTT CGC CCC)2Effect InferredPoor drug metabolizer. For individual with two non-functional alleles, dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*42Not Available3259_3260insGTEffect InferredPoor drug metabolizer. For individual with two non-functional alleles, dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*44Not Available2950G>CEffect InferredPoor drug metabolizer. For individual with two non-functional alleles, dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*47Not Available100C>T / -1426C>T  … show all Effect InferredPoor drug metabolizer. For individual with two non-functional alleles, dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*51Not Available-1584C>G / -1235A>G  … show all Effect InferredPoor drug metabolizer. For individual with two non-functional alleles, dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*56Not Available3201C>TEffect InferredPoor drug metabolizer. For individual with two non-functional alleles, dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*57Not Available100C>T / 310G>T  … show all Effect InferredPoor drug metabolizer. For individual with two non-functional alleles, dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*62Not Available4044C>TEffect InferredPoor drug metabolizer. For individual with two non-functional alleles, dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*68ANot Available-1426C>T / -1235A>G  … show all Effect InferredPoor drug metabolizer. For individual with two non-functional alleles, dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*68BNot AvailableSimilar but not identical switch region compared to CYP2D6*68A. Found in tandem arrangement with CYP2D6*4.Effect InferredPoor drug metabolizer. For individual with two non-functional alleles, dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*69Not Available2988G>A / -1426C>T  … show all Effect InferredPoor drug metabolizer. For individual with two non-functional alleles, dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*92Not Available1995delCEffect InferredPoor drug metabolizer. For individual with two non-functional alleles, dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*100Not Available-1426C>T / -1235A>G  … show all Effect InferredPoor drug metabolizer. For individual with two non-functional alleles, dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*101Not Available-1426C>T / -1235A>G  … show all Effect InferredPoor drug metabolizer. For individual with two non-functional alleles, dose reduction recommended.Details
Cytochrome P450 2C19CYP2C19*2ANot Available681G>AEffect InferredPoor drug metabolizer. For individual with two non-functional alleles, dose reduction recommended.Details
Cytochrome P450 2C19CYP2C19*2BNot Available681G>AEffect InferredPoor drug metabolizer. For individual with two non-functional alleles, dose reduction recommended.Details
Cytochrome P450 2C19CYP2C19*4Not Available1A>GEffect InferredPoor drug metabolizer. For individual with two non-functional alleles, dose reduction recommended.Details
Cytochrome P450 2C19CYP2C19*5Not Available1297C>TEffect InferredPoor drug metabolizer. For individual with two non-functional alleles, dose reduction recommended.Details
Cytochrome P450 2C19CYP2C19*6Not Available395G>AEffect InferredPoor drug metabolizer. For individual with two non-functional alleles, dose reduction recommended.Details
Cytochrome P450 2C19CYP2C19*7Not Available19294T>AEffect InferredPoor drug metabolizer. For individual with two non-functional alleles, dose reduction recommended.Details
Cytochrome P450 2C19CYP2C19*22Not Available557G>C / 991A>GEffect InferredPoor drug metabolizer. For individual with two non-functional alleles, dose reduction recommended.Details
Cytochrome P450 2C19CYP2C19*24Not Available99C>T / 991A>G  … show all Effect InferredPoor drug metabolizer. For individual with two non-functional alleles, dose reduction recommended.Details
Cytochrome P450 2C19CYP2C19*35Not Available12662A>GEffect InferredPoor drug metabolizer. For individual with two non-functional alleles, dose reduction recommended.Details
Cytochrome P450 2D6CYP2D6*3Not AvailableC alleleEffect InferredPoor drug metabolizer, lower dose requirements, higher risk for adverse side effectsDetails
Cytochrome P450 2D6CYP2D6*5Not AvailableWhole-gene deletionEffect InferredPoor drug metabolizer, lower dose requirements, higher risk for adverse side effectsDetails
Cytochrome P450 2D6CYP2D6*6Not Available1707delTEffect InferredPoor drug metabolizer, lower dose requirements, higher risk for adverse side effectsDetails
Cytochrome P450 2D6CYP2D6*7Not Available2935A>CEffect InferredPoor drug metabolizer, lower dose requirements, higher risk for adverse side effectsDetails
Cytochrome P450 2D6CYP2D6*8Not Available1758G>TEffect InferredPoor drug metabolizer, lower dose requirements, higher risk for adverse side effectsDetails
Cytochrome P450 2D6CYP2D6*11Not Available883G>CEffect InferredPoor drug metabolizer, lower dose requirements, higher risk for adverse side effectsDetails
Cytochrome P450 2D6CYP2D6*12Not Available124G>AEffect InferredPoor drug metabolizer, lower dose requirements, higher risk for adverse side effectsDetails
Cytochrome P450 2D6CYP2D6*13Not AvailableCYP2D7/2D6 hybrid gene structureEffect InferredPoor drug metabolizer, lower dose requirements, higher risk for adverse side effectsDetails
Cytochrome P450 2D6CYP2D6*14ANot Available1758G>AEffect InferredPoor drug metabolizer, lower dose requirements, higher risk for adverse side effectsDetails
Cytochrome P450 2D6CYP2D6*15Not Available137insT, 137_138insTEffect InferredPoor drug metabolizer, lower dose requirements, higher risk for adverse side effectsDetails
Cytochrome P450 2D6CYP2D6*19Not Available2539_2542delAACTEffect InferredPoor drug metabolizer, lower dose requirements, higher risk for adverse side effectsDetails
Cytochrome P450 2D6CYP2D6*20Not Available1973_1974insGEffect InferredPoor drug metabolizer, lower dose requirements, higher risk for adverse side effectsDetails
Cytochrome P450 2D6CYP2D6*21Not Available2573insCEffect InferredPoor drug metabolizer, lower dose requirements, higher risk for adverse side effectsDetails
Cytochrome P450 2D6CYP2D6*31Not Available-1770G>A / -1584C>G  … show all Effect InferredPoor drug metabolizer, lower dose requirements, higher risk for adverse side effectsDetails
Cytochrome P450 2D6CYP2D6*36Not Available100C>T / -1426C>T  … show all Effect InferredPoor drug metabolizer, lower dose requirements, higher risk for adverse side effectsDetails
Cytochrome P450 2D6CYP2D6*38Not Available2587_2590delGACTEffect InferredPoor drug metabolizer, lower dose requirements, higher risk for adverse side effectsDetails
Cytochrome P450 2D6CYP2D6*40Not Available1863_1864ins(TTT CGC CCC)2Effect InferredPoor drug metabolizer, lower dose requirements, higher risk for adverse side effectsDetails
Cytochrome P450 2D6CYP2D6*42Not Available3259_3260insGTEffect InferredPoor drug metabolizer, lower dose requirements, higher risk for adverse side effectsDetails
Cytochrome P450 2D6CYP2D6*44Not Available2950G>CEffect InferredPoor drug metabolizer, lower dose requirements, higher risk for adverse side effectsDetails
Cytochrome P450 2D6CYP2D6*47Not Available100C>T / -1426C>T  … show all Effect InferredPoor drug metabolizer, lower dose requirements, higher risk for adverse side effectsDetails
Cytochrome P450 2D6CYP2D6*51Not Available-1584C>G / -1235A>G  … show all Effect InferredPoor drug metabolizer, lower dose requirements, higher risk for adverse side effectsDetails
Cytochrome P450 2D6CYP2D6*56Not Available3201C>TEffect InferredPoor drug metabolizer, lower dose requirements, higher risk for adverse side effectsDetails
Cytochrome P450 2D6CYP2D6*57Not Available100C>T / 310G>T  … show all Effect InferredPoor drug metabolizer, lower dose requirements, higher risk for adverse side effectsDetails
Cytochrome P450 2D6CYP2D6*62Not Available4044C>TEffect InferredPoor drug metabolizer, lower dose requirements, higher risk for adverse side effectsDetails
Cytochrome P450 2D6CYP2D6*68ANot Available-1426C>T / -1235A>G  … show all Effect InferredPoor drug metabolizer, lower dose requirements, higher risk for adverse side effectsDetails
Cytochrome P450 2D6CYP2D6*68BNot AvailableSimilar but not identical switch region compared to CYP2D6*68A. Found in tandem arrangement with CYP2D6*4.Effect InferredPoor drug metabolizer, lower dose requirements, higher risk for adverse side effectsDetails
Cytochrome P450 2D6CYP2D6*69Not Available2988G>A / -1426C>T  … show all Effect InferredPoor drug metabolizer, lower dose requirements, higher risk for adverse side effectsDetails
Cytochrome P450 2D6CYP2D6*92Not Available1995delCEffect InferredPoor drug metabolizer, lower dose requirements, higher risk for adverse side effectsDetails
Cytochrome P450 2D6CYP2D6*100Not Available-1426C>T / -1235A>G  … show all Effect InferredPoor drug metabolizer, lower dose requirements, higher risk for adverse side effectsDetails
Cytochrome P450 2D6CYP2D6*101Not Available-1426C>T / -1235A>G  … show all Effect InferredPoor drug metabolizer, lower dose requirements, higher risk for adverse side effectsDetails
Cytochrome P450 2D6CYP2D6*3Not AvailableG alleleEffect Directly StudiedThe presence of this polymorphism in CYP2D6 is associated with poor metabolism of imipramine.Details
Cytochrome P450 2D6CYP2D6*4Not Available3877G>AEffect Directly StudiedThe presence of this polymorphism in CYP2D6 is associated with poor metabolism of imipramine.Details

Interactions

Drug Interactions
DrugInteractionDrug group
1,10-PhenanthrolineThe serum concentration of Imipramine can be increased when it is combined with 1,10-Phenanthroline.Experimental
2,5-Dimethoxy-4-ethylamphetamineImipramine may increase the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.Experimental, Illicit
3,4-DichloroisocoumarinThe serum concentration of Imipramine can be increased when it is combined with 3,4-Dichloroisocoumarin.Experimental
3,4-MethylenedioxyamphetamineImipramine may increase the stimulatory activities of 3,4-Methylenedioxyamphetamine.Experimental, Illicit
4-(2-Aminoethyl)Benzenesulfonyl FluorideThe serum concentration of Imipramine can be increased when it is combined with 4-(2-Aminoethyl)Benzenesulfonyl Fluoride.Experimental
4-Bromo-2,5-dimethoxyamphetamineImipramine may increase the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Experimental, Illicit
4-MethoxyamphetamineImipramine may decrease the antihypertensive activities of 4-Methoxyamphetamine.Experimental, Illicit
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Imipramine.Experimental
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the serotonergic activities of Imipramine.Experimental
AbirateroneThe serum concentration of Imipramine can be increased when it is combined with Abiraterone.Approved
AcebutololThe risk or severity of adverse effects can be increased when Imipramine is combined with Acebutolol.Approved
AcenocoumarolImipramine may increase the anticoagulant activities of Acenocoumarol.Approved
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Imipramine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Imipramine.Approved
AcetaminophenThe metabolism of Acetaminophen can be decreased when combined with Imipramine.Approved
AcetophenazineThe risk or severity of adverse effects can be increased when Imipramine is combined with Acetophenazine.Approved
AcetylcholineThe metabolism of Acetylcholine can be decreased when combined with Imipramine.Approved
AdipiplonThe risk or severity of adverse effects can be increased when Adipiplon is combined with Imipramine.Investigational
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Imipramine.Approved
AgmatineImipramine may decrease the antihypertensive activities of Agmatine.Experimental, Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Imipramine.Approved, Investigational
AjmalineThe metabolism of Ajmaline can be decreased when combined with Imipramine.Approved, Investigational
AlaproclateThe risk or severity of adverse effects can be increased when Imipramine is combined with Alaproclate.Experimental
AldesleukinThe risk or severity of adverse effects can be increased when Imipramine is combined with Aldesleukin.Approved
AlfaxaloneThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Imipramine.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Imipramine.Approved, Illicit
AliskirenThe risk or severity of adverse effects can be increased when Imipramine is combined with Aliskiren.Approved, Investigational
AllopregnanoloneThe risk or severity of adverse effects can be increased when Allopregnanolone is combined with Imipramine.Investigational
AlmotriptanThe risk or severity of adverse effects can be increased when Imipramine is combined with Almotriptan.Approved, Investigational
AlogliptinThe serum concentration of Imipramine can be increased when it is combined with Alogliptin.Approved
Alpha-1-proteinase inhibitorThe serum concentration of Imipramine can be increased when it is combined with Alpha-1-proteinase inhibitor.Approved
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Imipramine.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Alphaprodine is combined with Imipramine.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Imipramine.Approved, Illicit, Investigational
AlprenololThe metabolism of Alprenolol can be decreased when combined with Imipramine.Approved, Withdrawn
AltretamineAltretamine may increase the orthostatic hypotensive activities of Imipramine.Approved
AmifostineThe risk or severity of adverse effects can be increased when Amifostine is combined with Imipramine.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Imipramine is combined with Amiloride.Approved
AminophenazoneThe metabolism of Aminophenazone can be decreased when combined with Imipramine.Approved, Withdrawn
AmiodaroneThe metabolism of Imipramine can be decreased when combined with Amiodarone.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Amisulpride is combined with Imipramine.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Imipramine.Approved
AmlodipineThe risk or severity of adverse effects can be increased when Imipramine is combined with Amlodipine.Approved
AmobarbitalThe metabolism of Imipramine can be increased when combined with Amobarbital.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Imipramine is combined with Amoxapine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Amperozide is combined with Imipramine.Experimental
AmphetamineThe metabolism of Amphetamine can be decreased when combined with Imipramine.Approved, Illicit
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Imipramine.Approved, Investigational
AmprenavirThe serum concentration of Imipramine can be increased when it is combined with Amprenavir.Approved
AmsacrineThe metabolism of Amsacrine can be decreased when combined with Imipramine.Approved
Amyl NitriteThe risk or severity of adverse effects can be increased when Imipramine is combined with Amyl Nitrite.Approved
AnagrelideImipramine may increase the QTc-prolonging activities of Anagrelide.Approved
AntipyrineThe metabolism of Antipyrine can be decreased when combined with Imipramine.Approved
Antithrombin III humanThe serum concentration of Imipramine can be increased when it is combined with Antithrombin III human.Approved
ApixabanThe serum concentration of Imipramine can be increased when it is combined with Apixaban.Approved
ApomorphineImipramine may decrease the antihypertensive activities of Apomorphine.Approved, Investigational
ApraclonidineImipramine may decrease the antihypertensive activities of Apraclonidine.Approved
AprepitantThe serum concentration of Imipramine can be increased when it is combined with Aprepitant.Approved, Investigational
AprindineThe metabolism of Aprindine can be decreased when combined with Imipramine.Approved
AprotininThe serum concentration of Imipramine can be increased when it is combined with Aprotinin.Approved, Withdrawn
ArbutamineThe risk or severity of adverse effects can be increased when Imipramine is combined with Arbutamine.Approved
ArformoterolThe metabolism of Arformoterol can be decreased when combined with Imipramine.Approved, Investigational
ArgatrobanThe serum concentration of Imipramine can be increased when it is combined with Argatroban.Approved, Investigational
AripiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Imipramine.Approved, Investigational
ArmodafinilThe metabolism of Imipramine can be decreased when combined with Armodafinil.Approved, Investigational
ArotinololThe risk or severity of adverse effects can be increased when Arotinolol is combined with Imipramine.Approved, Investigational
Arsenic trioxideImipramine may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Investigational
ArtemetherImipramine may increase the QTc-prolonging activities of Artemether.Approved
ArticaineThe risk or severity of adverse effects can be increased when Articaine is combined with Imipramine.Approved
AsenapineImipramine may increase the QTc-prolonging activities of Asenapine.Approved
AstemizoleThe metabolism of Astemizole can be decreased when combined with Imipramine.Approved, Withdrawn
AsunaprevirThe serum concentration of Imipramine can be increased when it is combined with Asunaprevir.Approved, Investigational
AtazanavirThe metabolism of Imipramine can be decreased when combined with Atazanavir.Approved, Investigational
AtenololThe risk or severity of adverse effects can be increased when Imipramine is combined with Atenolol.Approved
AtomoxetineThe metabolism of Imipramine can be decreased when combined with Atomoxetine.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Azaperone is combined with Imipramine.Investigational, Vet Approved
AzelastineImipramine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Imipramine is combined with Azilsartan medoxomil.Approved
AzithromycinImipramine may increase the QTc-prolonging activities of Azithromycin.Approved
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Imipramine.Approved
BambuterolThe risk or severity of adverse effects can be increased when Imipramine is combined with Bambuterol.Approved, Investigational
BarbexacloneThe metabolism of Imipramine can be increased when combined with Barbexaclone.Experimental
BarbitalThe metabolism of Imipramine can be increased when combined with Barbital.Illicit
BarnidipineThe risk or severity of adverse effects can be increased when Barnidipine is combined with Imipramine.Approved
BatimastatThe serum concentration of Imipramine can be increased when it is combined with Batimastat.Experimental
BedaquilineImipramine may increase the QTc-prolonging activities of Bedaquiline.Approved
BenazeprilThe serum concentration of Imipramine can be increased when it is combined with Benazepril.Approved, Investigational
BendroflumethiazideThe risk or severity of adverse effects can be increased when Imipramine is combined with Bendroflumethiazide.Approved
BenmoxinBenmoxin may increase the serotonergic activities of Imipramine.Withdrawn
BenperidolThe risk or severity of adverse effects can be increased when Benperidol is combined with Imipramine.Investigational
BenzamidineThe serum concentration of Imipramine can be increased when it is combined with Benzamidine.Experimental
BenzatropineThe metabolism of Benzatropine can be decreased when combined with Imipramine.Approved
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Imipramine.Approved
BenzphetamineImipramine may decrease the antihypertensive activities of Benzphetamine.Approved, Illicit
Benzyl alcoholThe metabolism of Benzyl alcohol can be decreased when combined with Imipramine.Approved
BepridilThe risk or severity of adverse effects can be increased when Bepridil is combined with Imipramine.Approved, Withdrawn
BetaxololThe metabolism of Betaxolol can be decreased when combined with Imipramine.Approved
BethanidineImipramine may decrease the antihypertensive activities of Bethanidine.Approved
BifeprunoxThe risk or severity of adverse effects can be increased when Imipramine is combined with Bifeprunox.Investigational
BisoprololThe metabolism of Bisoprolol can be decreased when combined with Imipramine.Approved
BivalirudinThe serum concentration of Imipramine can be increased when it is combined with Bivalirudin.Approved, Investigational
BoceprevirThe metabolism of Imipramine can be decreased when combined with Boceprevir.Approved, Withdrawn
BortezomibThe metabolism of Imipramine can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Imipramine can be decreased when it is combined with Bosentan.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Imipramine.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Imipramine.Approved
BretyliumThe risk or severity of adverse effects can be increased when Imipramine is combined with Bretylium.Approved
BrexpiprazoleThe serum concentration of Brexpiprazole can be increased when it is combined with Imipramine.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Imipramine.Approved
BrofaromineBrofaromine may increase the serotonergic activities of Imipramine.Experimental
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Imipramine.Approved, Illicit
BromisovalThe risk or severity of adverse effects can be increased when Bromisoval is combined with Imipramine.Experimental
BromocriptineImipramine may decrease the antihypertensive activities of Bromocriptine.Approved, Investigational
BromperidolThe risk or severity of adverse effects can be increased when Imipramine is combined with Bromperidol.Investigational
BrompheniramineThe metabolism of Brompheniramine can be decreased when combined with Imipramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Brotizolam is combined with Imipramine.Approved, Investigational, Withdrawn
BufuralolThe metabolism of Bufuralol can be decreased when combined with Imipramine.Experimental, Investigational
BumetanideThe risk or severity of adverse effects can be increased when Imipramine is combined with Bumetanide.Approved
BupivacaineThe metabolism of Bupivacaine can be decreased when combined with Imipramine.Approved, Investigational
BuprenorphineImipramine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BupropionThe metabolism of Imipramine can be decreased when combined with Bupropion.Approved
BuspironeThe risk or severity of adverse effects can be increased when Imipramine is combined with Buspirone.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Imipramine.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Butacaine is combined with Imipramine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Imipramine.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Butamben is combined with Imipramine.Approved
ButaperazineThe risk or severity of adverse effects can be increased when Imipramine is combined with Butaperazine.Experimental
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Imipramine.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Imipramine.Approved, Illicit, Vet Approved
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Imipramine.Approved
CaffeineThe metabolism of Imipramine can be decreased when combined with Caffeine.Approved
CamostatThe serum concentration of Imipramine can be increased when it is combined with Camostat.Experimental
CanagliflozinThe risk or severity of adverse effects can be increased when Imipramine is combined with Canagliflozin.Approved
Candesartan cilexetilThe risk or severity of adverse effects can be increased when Imipramine is combined with Candesartan cilexetil.Approved
CandoxatrilThe serum concentration of Imipramine can be increased when it is combined with Candoxatril.Experimental
CandoxatrilatThe serum concentration of Imipramine can be increased when it is combined with Candoxatrilat.Experimental
CanertinibThe risk or severity of adverse effects can be increased when Canertinib is combined with Imipramine.Investigational
CaptoprilThe serum concentration of Imipramine can be increased when it is combined with Captopril.Approved
CarbamazepineThe metabolism of Imipramine can be increased when combined with Carbamazepine.Approved, Investigational
CarbetocinThe risk or severity of adverse effects can be increased when Carbetocin is combined with Imipramine.Approved
CarbinoxamineThe risk or severity of adverse effects can be increased when Imipramine is combined with Carbinoxamine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Imipramine.Illicit, Investigational, Vet Approved
CariprazineThe metabolism of Cariprazine can be decreased when combined with Imipramine.Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Imipramine.Approved
CaroxazoneCaroxazone may increase the serotonergic activities of Imipramine.Withdrawn
CarteololThe metabolism of Carteolol can be decreased when combined with Imipramine.Approved
CarvedilolThe risk or severity of adverse effects can be increased when Imipramine is combined with Carvedilol.Approved, Investigational
CelecoxibThe metabolism of Imipramine can be decreased when combined with Celecoxib.Approved, Investigational
CeliprololThe risk or severity of adverse effects can be increased when Imipramine is combined with Celiprolol.Approved, Investigational
CephalexinThe metabolism of Cephalexin can be decreased when combined with Imipramine.Approved, Vet Approved
CeritinibThe serum concentration of Imipramine can be increased when it is combined with Ceritinib.Approved
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Imipramine.Approved
CevimelineThe metabolism of Cevimeline can be decreased when combined with Imipramine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Imipramine.Approved, Illicit, Vet Approved
ChloramphenicolThe metabolism of Imipramine can be decreased when combined with Chloramphenicol.Approved, Vet Approved
ChlordiazepoxideThe metabolism of Chlordiazepoxide can be decreased when combined with Imipramine.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Imipramine.Approved, Investigational, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Imipramine.Approved
ChloroquineImipramine may increase the QTc-prolonging activities of Chloroquine.Approved, Vet Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Imipramine is combined with Chlorothiazide.Approved, Vet Approved
ChlorphenamineThe metabolism of Chlorphenamine can be decreased when combined with Imipramine.Approved
ChlorphentermineImipramine may increase the stimulatory activities of Chlorphentermine.Illicit, Withdrawn
ChlorproethazineThe risk or severity of adverse effects can be increased when Imipramine is combined with Chlorproethazine.Experimental
ChlorpromazineImipramine may increase the QTc-prolonging activities of Chlorpromazine.Approved, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Imipramine.Approved, Investigational, Withdrawn
ChlorthalidoneThe risk or severity of adverse effects can be increased when Imipramine is combined with Chlorthalidone.Approved
ChlorzoxazoneThe metabolism of Chlorzoxazone can be decreased when combined with Imipramine.Approved
CholecalciferolThe metabolism of Imipramine can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CholesterolThe serum concentration of Imipramine can be increased when it is combined with Cholesterol.Experimental, Investigational
ChymostatinThe serum concentration of Imipramine can be increased when it is combined with Chymostatin.Experimental
CilastatinThe serum concentration of Imipramine can be increased when it is combined with Cilastatin.Approved
CilazaprilThe serum concentration of Imipramine can be increased when it is combined with Cilazapril.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Imipramine.Approved, Investigational
CilostazolThe serum concentration of Cilostazol can be increased when it is combined with Imipramine.Approved
CimetidineThe metabolism of Imipramine can be decreased when combined with Cimetidine.Approved
CinacalcetThe serum concentration of Imipramine can be increased when it is combined with Cinacalcet.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Imipramine.Approved, Vet Approved
CinnarizineThe metabolism of Cinnarizine can be decreased when combined with Imipramine.Approved, Investigational
CiprofloxacinImipramine may increase the QTc-prolonging activities of Ciprofloxacin.Approved, Investigational
CirazolineImipramine may increase the vasopressor activities of Cirazoline.Experimental
CisaprideImipramine may increase the QTc-prolonging activities of Cisapride.Approved, Investigational, Withdrawn
CitalopramThe risk or severity of adverse effects can be increased when Imipramine is combined with Citalopram.Approved
ClarithromycinThe metabolism of Imipramine can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Imipramine can be decreased when combined with Clemastine.Approved
ClenbuterolThe risk or severity of adverse effects can be increased when Imipramine is combined with Clenbuterol.Approved, Investigational, Vet Approved
ClevidipineThe metabolism of Clevidipine can be decreased when combined with Imipramine.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Imipramine is combined with Clidinium.Approved
ClobazamThe metabolism of Imipramine can be decreased when combined with Clobazam.Approved, Illicit
ClofarabineThe risk or severity of adverse effects can be increased when Clofarabine is combined with Imipramine.Approved, Investigational
clomethiazoleThe risk or severity of adverse effects can be increased when clomethiazole is combined with Imipramine.Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Clomipramine.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Imipramine is combined with Clonazepam.Approved, Illicit
ClonidineImipramine may decrease the antihypertensive activities of Clonidine.Approved
ClopenthixolThe risk or severity of adverse effects can be increased when Clopenthixol is combined with Imipramine.Experimental
ClopidogrelThe metabolism of Imipramine can be decreased when combined with Clopidogrel.Approved, Nutraceutical
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Imipramine.Approved, Illicit
ClorindioneImipramine may increase the anticoagulant activities of Clorindione.Experimental
ClothiapineThe risk or severity of adverse effects can be increased when Clothiapine is combined with Imipramine.Experimental
ClotrimazoleThe metabolism of Imipramine can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineImipramine may increase the QTc-prolonging activities of Clozapine.Approved
CobicistatThe serum concentration of Imipramine can be increased when it is combined with Cobicistat.Approved
CocaineThe metabolism of Imipramine can be decreased when combined with Cocaine.Approved, Illicit
CodeineThe therapeutic efficacy of Codeine can be decreased when used in combination with Imipramine.Approved, Illicit
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Imipramine.Approved
ConivaptanThe serum concentration of Imipramine can be increased when it is combined with Conivaptan.Approved, Investigational
CrizotinibImipramine may increase the QTc-prolonging activities of Crizotinib.Approved
CyamemazineThe risk or severity of adverse effects can be increased when Imipramine is combined with Cyamemazine.Approved
CyclizineThe risk or severity of adverse effects can be increased when Imipramine is combined with Cyclizine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Imipramine is combined with Cyclobenzaprine.Approved
CyclophosphamideThe metabolism of Cyclophosphamide can be decreased when combined with Imipramine.Approved, Investigational
CyclosporineThe metabolism of Imipramine can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Imipramine.Approved
Cyproterone acetateThe serum concentration of Imipramine can be decreased when it is combined with Cyproterone acetate.Approved, Investigational
Dabigatran etexilateThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Imipramine.Approved
DabrafenibThe serum concentration of Imipramine can be decreased when it is combined with Dabrafenib.Approved
DantroleneThe risk or severity of adverse effects can be increased when Imipramine is combined with Dantrolene.Approved
DapagliflozinThe risk or severity of adverse effects can be increased when Imipramine is combined with Dapagliflozin.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Imipramine.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Imipramine.Investigational
DarexabanThe serum concentration of Imipramine can be increased when it is combined with Darexaban.Investigational
DarifenacinThe metabolism of Imipramine can be decreased when combined with Darifenacin.Approved, Investigational
DarunavirThe serum concentration of Imipramine can be increased when it is combined with Darunavir.Approved
DasabuvirThe metabolism of Dasabuvir can be decreased when combined with Imipramine.Approved
DasatinibThe serum concentration of Imipramine can be increased when it is combined with Dasatinib.Approved, Investigational
DebrisoquinThe metabolism of Debrisoquin can be decreased when combined with Imipramine.Approved, Investigational
DeferasiroxThe serum concentration of Imipramine can be decreased when it is combined with Deferasirox.Approved, Investigational
DelanzomibThe serum concentration of Imipramine can be increased when it is combined with Delanzomib.Investigational
DelaprilThe serum concentration of Imipramine can be increased when it is combined with Delapril.Experimental
DelavirdineThe metabolism of Imipramine can be decreased when combined with Delavirdine.Approved
DeramciclaneThe risk or severity of adverse effects can be increased when Deramciclane is combined with Imipramine.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Imipramine.Approved
DesipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Desipramine.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Imipramine is combined with Desloratadine.Approved, Investigational
DesmopressinThe risk or severity of adverse effects can be increased when Imipramine is combined with Desmopressin.Approved
DesvenlafaxineThe risk or severity of adverse effects can be increased when Imipramine is combined with Desvenlafaxine.Approved
DetomidineThe risk or severity of adverse effects can be increased when Detomidine is combined with Imipramine.Vet Approved
DeutetrabenazineThe metabolism of Deutetrabenazine can be decreased when combined with Imipramine.Approved, Investigational
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Imipramine.Approved
Dexchlorpheniramine maleateThe metabolism of Dexchlorpheniramine maleate can be decreased when combined with Imipramine.Approved
DexfenfluramineThe metabolism of Dexfenfluramine can be decreased when combined with Imipramine.Approved, Illicit, Investigational, Withdrawn
DexmedetomidineImipramine may decrease the antihypertensive activities of Dexmedetomidine.Approved, Vet Approved
DexmethylphenidateThe risk or severity of adverse effects can be increased when Dexmethylphenidate is combined with Imipramine.Approved
DextroamphetamineThe metabolism of Dextroamphetamine can be decreased when combined with Imipramine.Approved, Illicit
DextromethorphanThe risk or severity of adverse effects can be increased when Imipramine is combined with Dextromethorphan.Approved
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Imipramine.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Imipramine.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Imipramine.Approved, Investigational
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Imipramine.Approved, Illicit, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Imipramine is combined with Diclofenamide.Approved
DicoumarolImipramine may increase the anticoagulant activities of Dicoumarol.Approved
Diethyl etherThe risk or severity of adverse effects can be increased when Diethyl ether is combined with Imipramine.Experimental
DiethylpropionImipramine may increase the stimulatory activities of Diethylpropion.Approved, Illicit
DifenoxinThe risk or severity of adverse effects can be increased when Imipramine is combined with Difenoxin.Approved, Illicit
DihydrocodeineThe metabolism of Dihydrocodeine can be decreased when combined with Imipramine.Approved, Illicit
DihydroergotamineImipramine may decrease the antihypertensive activities of Dihydroergotamine.Approved
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Imipramine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Imipramine.Experimental, Illicit
DiltiazemThe metabolism of Imipramine can be decreased when combined with Diltiazem.Approved
DimenhydrinateThe risk or severity of adverse effects can be increased when Imipramine is combined with Dimenhydrinate.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Imipramine is combined with Dinutuximab.Approved
DiphenadioneImipramine may increase the anticoagulant activities of Diphenadione.Experimental
DiphenhydramineThe metabolism of Imipramine can be decreased when combined with Diphenhydramine.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Imipramine.Approved, Illicit
DipivefrinImipramine may decrease the antihypertensive activities of Dipivefrin.Approved
DipyridamoleThe risk or severity of adverse effects can be increased when Imipramine is combined with Dipyridamole.Approved
DisopyramideImipramine may increase the QTc-prolonging activities of Disopyramide.Approved
DixyrazineThe risk or severity of adverse effects can be increased when Dixyrazine is combined with Imipramine.Experimental
DobutamineThe risk or severity of adverse effects can be increased when Imipramine is combined with Dobutamine.Approved
DofetilideImipramine may increase the QTc-prolonging activities of Dofetilide.Approved
DolasetronImipramine may increase the QTc-prolonging activities of Dolasetron.Approved
DomperidoneImipramine may increase the QTc-prolonging activities of Domperidone.Approved, Investigational, Vet Approved
DonepezilThe metabolism of Donepezil can be decreased when combined with Imipramine.Approved
DopamineThe metabolism of Dopamine can be decreased when combined with Imipramine.Approved
DoramectinThe risk or severity of adverse effects can be increased when Doramectin is combined with Imipramine.Vet Approved
DosulepinThe metabolism of Imipramine can be decreased when combined with Dosulepin.Approved
DoxazosinThe risk or severity of adverse effects can be increased when Imipramine is combined with Doxazosin.Approved
DoxepinThe risk or severity of adverse effects can be increased when Imipramine is combined with Doxepin.Approved
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Imipramine.Approved, Investigational
DoxorubicinThe metabolism of Doxorubicin can be decreased when combined with Imipramine.Approved, Investigational
DoxycyclineThe metabolism of Imipramine can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Imipramine.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Imipramine.Experimental
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Imipramine.Approved, Illicit
DronedaroneImipramine may increase the QTc-prolonging activities of Dronedarone.Approved
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Imipramine.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Imipramine.Experimental, Illicit
DroxidopaImipramine may decrease the antihypertensive activities of Droxidopa.Approved, Investigational
DuloxetineDuloxetine may increase the serotonergic activities of Imipramine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Imipramine.Approved
EcabetThe serum concentration of Imipramine can be increased when it is combined with Ecabet.Approved, Investigational
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Imipramine.Experimental, Illicit
EcopipamThe risk or severity of adverse effects can be increased when Ecopipam is combined with Imipramine.Investigational
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Imipramine.Approved
EfavirenzThe risk or severity of adverse effects can be increased when Imipramine is combined with Efavirenz.Approved, Investigational
EfonidipineThe risk or severity of adverse effects can be increased when Efonidipine is combined with Imipramine.Approved, Investigational
ElafinThe serum concentration of Imipramine can be increased when it is combined with Elafin.Investigational
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Imipramine.Approved, Investigational
EliglustatThe serum concentration of Eliglustat can be increased when it is combined with Imipramine.Approved
EltanoloneThe risk or severity of adverse effects can be increased when Eltanolone is combined with Imipramine.Investigational
EmpagliflozinThe risk or severity of adverse effects can be increased when Imipramine is combined with Empagliflozin.Approved
EnalaprilThe serum concentration of Imipramine can be increased when it is combined with Enalapril.Approved, Vet Approved
EnalaprilatThe serum concentration of Imipramine can be increased when it is combined with Enalaprilat.Approved
EnalkirenThe serum concentration of Imipramine can be increased when it is combined with Enalkiren.Experimental
EnasidenibThe metabolism of Enasidenib can be decreased when combined with Imipramine.Approved
EncainideThe metabolism of Encainide can be decreased when combined with Imipramine.Approved, Investigational, Withdrawn
EnclomipheneThe metabolism of Enclomiphene can be decreased when combined with Imipramine.Investigational
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Imipramine.Approved, Investigational, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Imipramine is combined with Entacapone.Approved, Investigational
EnzalutamideThe serum concentration of Imipramine can be decreased when it is combined with Enzalutamide.Approved
EphedraImipramine may decrease the antihypertensive activities of Ephedra.Approved, Nutraceutical, Withdrawn
Epigallocatechin GallateThe serum concentration of Imipramine can be increased when it is combined with Epigallocatechin Gallate.Investigational
EpinastineThe metabolism of Epinastine can be decreased when combined with Imipramine.Approved, Investigational
EpinephrineImipramine may decrease the antihypertensive activities of Epinephrine.Approved, Vet Approved
EplerenoneThe risk or severity of adverse effects can be increased when Imipramine is combined with Eplerenone.Approved
EpoprostenolThe risk or severity of adverse effects can be increased when Epoprostenol is combined with Imipramine.Approved
EprosartanThe risk or severity of adverse effects can be increased when Imipramine is combined with Eprosartan.Approved
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Imipramine is combined with Ergoloid mesylate.Approved
ErgonovineThe risk or severity of adverse effects can be increased when Imipramine is combined with Ergonovine.Approved
ErgotamineImipramine may decrease the antihypertensive activities of Ergotamine.Approved
ErlotinibThe metabolism of Erlotinib can be decreased when combined with Imipramine.Approved, Investigational
ErythromycinImipramine may increase the QTc-prolonging activities of Erythromycin.Approved, Vet Approved
EscitalopramThe risk or severity of adverse effects can be increased when Imipramine is combined with Escitalopram.Approved, Investigational
Eslicarbazepine acetateThe metabolism of Imipramine can be decreased when combined with Eslicarbazepine acetate.Approved
EsmirtazapineThe metabolism of Esmirtazapine can be decreased when combined with Imipramine.Investigational
EsmololThe risk or severity of adverse effects can be increased when Imipramine is combined with Esmolol.Approved
EsomeprazoleThe metabolism of Imipramine can be decreased when combined with Esomeprazole.Approved, Investigational
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Imipramine.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Imipramine.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Imipramine is combined with Etacrynic acid.Approved
EthanolImipramine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Imipramine.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Imipramine is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Imipramine is combined with Ethotoin.Approved
Ethyl biscoumacetateImipramine may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Imipramine.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Ethyl chloride is combined with Imipramine.Experimental, Investigational
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Imipramine.Approved, Illicit
EthylmorphineThe metabolism of Ethylmorphine can be decreased when combined with Imipramine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Etidocaine is combined with Imipramine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Etifoxine is combined with Imipramine.Investigational, Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Etizolam is combined with Imipramine.Approved
EtomidateImipramine may decrease the antihypertensive activities of Etomidate.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Imipramine is combined with Etoperidone.Withdrawn
EtoricoxibThe metabolism of Etoricoxib can be decreased when combined with Imipramine.Approved, Investigational
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Imipramine.Illicit, Vet Approved
EtravirineThe metabolism of Imipramine can be decreased when combined with Etravirine.Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Imipramine.Approved
EzogabineThe risk or severity of adverse effects can be increased when Imipramine is combined with Ezogabine.Approved
FaldaprevirThe serum concentration of Imipramine can be increased when it is combined with Faldaprevir.Investigational
FelbamateThe risk or severity of adverse effects can be increased when Imipramine is combined with Felbamate.Approved
FelodipineThe risk or severity of adverse effects can be increased when Imipramine is combined with Felodipine.Approved, Investigational
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Imipramine.Approved, Illicit, Withdrawn
FenoldopamThe risk or severity of adverse effects can be increased when Fenoldopam is combined with Imipramine.Approved
FenoterolThe risk or severity of adverse effects can be increased when Imipramine is combined with Fenoterol.Approved, Investigational
FentanylThe risk or severity of adverse effects can be increased when Imipramine is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Imipramine.Approved
FexofenadineThe risk or severity of adverse effects can be increased when Imipramine is combined with Fexofenadine.Approved
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Imipramine.Approved, Investigational
FingolimodThe metabolism of Fingolimod can be decreased when combined with Imipramine.Approved, Investigational
FlecainideImipramine may increase the QTc-prolonging activities of Flecainide.Approved, Withdrawn
FlibanserinThe risk or severity of adverse effects can be increased when Imipramine is combined with Flibanserin.Approved
FluanisoneThe risk or severity of adverse effects can be increased when Fluanisone is combined with Imipramine.Experimental
FluconazoleThe metabolism of Imipramine can be decreased when combined with Fluconazole.Approved
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Imipramine.Approved, Illicit
FluindioneImipramine may increase the anticoagulant activities of Fluindione.Investigational
FlunarizineThe metabolism of Flunarizine can be decreased when combined with Imipramine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Imipramine.Approved, Illicit
FluoxetineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Imipramine.Approved, Vet Approved
FlupentixolImipramine may increase the QTc-prolonging activities of Flupentixol.Approved, Withdrawn
FluphenazineThe metabolism of Fluphenazine can be decreased when combined with Imipramine.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Imipramine.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Imipramine.Approved, Investigational
Fluticasone propionateThe risk or severity of adverse effects can be increased when Imipramine is combined with Fluticasone propionate.Approved
FluvastatinThe metabolism of Fluvastatin can be decreased when combined with Imipramine.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Imipramine.Approved, Investigational
FormoterolThe metabolism of Formoterol can be decreased when combined with Imipramine.Approved, Investigational
FosamprenavirThe serum concentration of Imipramine can be increased when it is combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Imipramine can be increased when it is combined with Fosaprepitant.Approved
FosinoprilThe serum concentration of Imipramine can be increased when it is combined with Fosinopril.Approved
FosphenytoinThe metabolism of Imipramine can be increased when combined with Fosphenytoin.Approved
FospropofolThe risk or severity of adverse effects can be increased when Fospropofol is combined with Imipramine.Approved, Illicit, Investigational
FrovatriptanThe risk or severity of adverse effects can be increased when Imipramine is combined with Frovatriptan.Approved, Investigational
FurazolidoneFurazolidone may increase the serotonergic activities of Imipramine.Approved, Investigational, Vet Approved
FurosemideThe risk or severity of adverse effects can be increased when Imipramine is combined with Furosemide.Approved, Vet Approved
Fusidic AcidThe serum concentration of Imipramine can be increased when it is combined with Fusidic Acid.Approved
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Imipramine.Approved, Investigational
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when Imipramine is combined with Gabapentin Enacarbil.Approved
GabexateThe serum concentration of Imipramine can be increased when it is combined with Gabexate.Investigational
Gadobenic acidImipramine may increase the QTc-prolonging activities of Gadobenic acid.Approved
GalantamineThe metabolism of Galantamine can be decreased when combined with Imipramine.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Imipramine.Approved, Illicit, Investigational
GefitinibThe metabolism of Gefitinib can be decreased when combined with Imipramine.Approved, Investigational
GeldanamycinThe serum concentration of Imipramine can be increased when it is combined with Geldanamycin.Experimental, Investigational
GemfibrozilThe metabolism of Imipramine can be decreased when combined with Gemfibrozil.Approved
GemifloxacinImipramine may increase the QTc-prolonging activities of Gemifloxacin.Approved, Investigational
GepefrineImipramine may increase the stimulatory activities of Gepefrine.Experimental
GepironeThe risk or severity of adverse effects can be increased when Gepirone is combined with Imipramine.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Imipramine.Approved, Illicit
GM6001The serum concentration of Imipramine can be increased when it is combined with GM6001.Experimental
GoserelinImipramine may increase the QTc-prolonging activities of Goserelin.Approved
GranisetronImipramine may increase the QTc-prolonging activities of Granisetron.Approved, Investigational
GuanabenzImipramine may decrease the antihypertensive activities of Guanabenz.Approved, Investigational
GuanfacineImipramine may decrease the antihypertensive activities of Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Imipramine.Approved, Illicit, Withdrawn
HalofantrineThe metabolism of Halofantrine can be decreased when combined with Imipramine.Approved
HaloperidolImipramine may increase the QTc-prolonging activities of Haloperidol.Approved
HalothaneThe metabolism of Halothane can be decreased when combined with Imipramine.Approved, Vet Approved
HarmalineHarmaline may increase the serotonergic activities of Imipramine.Experimental
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Imipramine.Approved, Illicit, Investigational
HexobarbitalThe metabolism of Imipramine can be increased when combined with Hexobarbital.Approved
HydracarbazineHydracarbazine may increase the serotonergic activities of Imipramine.Experimental
HydralazineThe risk or severity of adverse effects can be increased when Imipramine is combined with Hydralazine.Approved
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Imipramine is combined with Hydrochlorothiazide.Approved, Vet Approved
HydrocodoneImipramine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydroflumethiazideThe risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Imipramine.Approved, Investigational
HydromorphoneThe metabolism of Hydromorphone can be decreased when combined with Imipramine.Approved, Illicit
HydroxyamphetamineImipramine may increase the stimulatory activities of Hydroxyamphetamine.Approved
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Imipramine.Approved
IbrutinibThe metabolism of Ibrutinib can be decreased when combined with Imipramine.Approved
IbutilideImipramine may increase the QTc-prolonging activities of Ibutilide.Approved
IdarubicinThe metabolism of Idarubicin can be decreased when combined with Imipramine.Approved
IdraparinuxThe serum concentration of Imipramine can be increased when it is combined with Idraparinux.Investigational
IloperidoneImipramine may increase the QTc-prolonging activities of Iloperidone.Approved
IloprostThe risk or severity of adverse effects can be increased when Iloprost is combined with Imipramine.Approved, Investigational
ImatinibThe metabolism of Imipramine can be decreased when combined with Imatinib.Approved
ImidaprilThe serum concentration of Imipramine can be increased when it is combined with Imidapril.Investigational
IndacaterolThe risk or severity of adverse effects can be increased when Imipramine is combined with Indacaterol.Approved
IndalpineThe risk or severity of adverse effects can be increased when Imipramine is combined with Indalpine.Investigational, Withdrawn
IndapamideThe risk or severity of adverse effects can be increased when Imipramine is combined with Indapamide.Approved
IndinavirThe metabolism of Imipramine can be decreased when combined with Indinavir.Approved
IndiplonThe risk or severity of adverse effects can be increased when Indiplon is combined with Imipramine.Investigational
IndoraminThe risk or severity of adverse effects can be increased when Imipramine is combined with Indoramin.Withdrawn
IobenguaneThe therapeutic efficacy of Iobenguane can be decreased when used in combination with Imipramine.Approved, Investigational
Iofetamine I-123Imipramine may increase the stimulatory activities of Iofetamine I-123.Approved
Ipratropium bromideThe metabolism of Ipratropium bromide can be decreased when combined with Imipramine.Approved
IproclozideIproclozide may increase the serotonergic activities of Imipramine.Withdrawn
IproniazidIproniazid may increase the serotonergic activities of Imipramine.Withdrawn
IrbesartanThe risk or severity of adverse effects can be increased when Imipramine is combined with Irbesartan.Approved, Investigational
IsavuconazoniumThe metabolism of Imipramine can be decreased when combined with Isavuconazonium.Approved, Investigational
IsocarboxazidThe risk or severity of adverse effects can be increased when Imipramine is combined with Isocarboxazid.Approved
IsoetarineThe risk or severity of adverse effects can be increased when Imipramine is combined with Isoetarine.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Imipramine.Approved, Vet Approved
IsoflurophateThe serum concentration of Imipramine can be increased when it is combined with Isoflurophate.Approved, Investigational, Withdrawn
IsoniazidThe metabolism of Imipramine can be decreased when combined with Isoniazid.Approved
IsoprenalineThe risk or severity of adverse effects can be increased when Imipramine is combined with Isoprenaline.Approved
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Imipramine is combined with Isosorbide Dinitrate.Approved
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Imipramine is combined with Isosorbide Mononitrate.Approved
IsoxsuprineThe risk or severity of adverse effects can be increased when Imipramine is combined with Isoxsuprine.Approved, Withdrawn
IsradipineThe metabolism of Imipramine can be decreased when combined with Isradipine.Approved
ItraconazoleThe metabolism of Imipramine can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Imipramine can be increased when it is combined with Ivacaftor.Approved
IxazomibThe serum concentration of Imipramine can be increased when it is combined with Ixazomib.Approved
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Imipramine.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Imipramine.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Imipramine.Approved, Investigational
KetoconazoleThe metabolism of Imipramine can be decreased when combined with Ketoconazole.Approved, Investigational
LabetalolThe metabolism of Labetalol can be decreased when combined with Imipramine.Approved
LacidipineThe risk or severity of adverse effects can be increased when Imipramine is combined with Lacidipine.Approved, Investigational
LamotrigineThe risk or severity of adverse effects can be increased when Imipramine is combined with Lamotrigine.Approved, Investigational
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Imipramine.Approved
LenvatinibImipramine may increase the QTc-prolonging activities of Lenvatinib.Approved
LepirudinThe serum concentration of Imipramine can be increased when it is combined with Lepirudin.Approved
LercanidipineThe risk or severity of adverse effects can be increased when Imipramine is combined with Lercanidipine.Approved, Investigational
LetaxabanThe serum concentration of Imipramine can be increased when it is combined with Letaxaban.Investigational
LetermovirThe metabolism of Letermovir can be decreased when combined with Imipramine.Approved
LeuprolideImipramine may increase the QTc-prolonging activities of Leuprolide.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Imipramine is combined with Levetiracetam.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Imipramine is combined with Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Imipramine.Approved, Investigational
LevocabastineThe risk or severity of adverse effects can be increased when Imipramine is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Imipramine is combined with Levocetirizine.Approved
LevodopaImipramine may increase the orthostatic hypotensive activities of Levodopa.Approved
LevofloxacinImipramine may increase the QTc-prolonging activities of Levofloxacin.Approved, Investigational
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Imipramine.Approved, Investigational
LevomilnacipranThe risk or severity of adverse effects can be increased when Imipramine is combined with Levomilnacipran.Approved
LevonordefrinImipramine may decrease the antihypertensive activities of Levonordefrin.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Imipramine.Approved
LevosalbutamolThe risk or severity of adverse effects can be increased when Imipramine is combined with Levosalbutamol.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Imipramine is combined with Levosimendan.Approved, Investigational
LevothyroxineLevothyroxine may increase the arrhythmogenic activities of Imipramine.Approved
LidocaineThe metabolism of Imipramine can be decreased when combined with Lidocaine.Approved, Vet Approved
LinagliptinThe serum concentration of Imipramine can be increased when it is combined with Linagliptin.Approved
LinezolidLinezolid may increase the serotonergic activities of Imipramine.Approved, Investigational
LiothyronineLiothyronine may increase the arrhythmogenic activities of Imipramine.Approved, Vet Approved
LiotrixLiotrix may increase the arrhythmogenic activities of Imipramine.Approved
LisdexamfetamineImipramine may increase the stimulatory activities of Lisdexamfetamine.Approved, Investigational
LisinoprilThe serum concentration of Imipramine can be increased when it is combined with Lisinopril.Approved, Investigational
LisurideThe metabolism of Lisuride can be decreased when combined with Imipramine.Approved, Investigational
LithiumLithium may increase the neurotoxic activities of Imipramine.Approved
LobeglitazoneThe metabolism of Imipramine can be decreased when combined with Lobeglitazone.Approved, Investigational
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Imipramine.Illicit
LofexidineImipramine may decrease the antihypertensive activities of Lofexidine.Approved, Investigational
LomustineThe metabolism of Lomustine can be decreased when combined with Imipramine.Approved
LoperamideThe metabolism of Loperamide can be decreased when combined with Imipramine.Approved
LopinavirThe metabolism of Imipramine can be decreased when combined with Lopinavir.Approved
LoprazolamThe risk or severity of adverse effects can be increased when Loprazolam is combined with Imipramine.Experimental
LoratadineThe metabolism of Loratadine can be decreased when combined with Imipramine.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Imipramine.Approved
LorcaserinThe risk or severity of adverse effects can be increased when Imipramine is combined with Lorcaserin.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Lormetazepam is combined with Imipramine.Approved
LosartanThe risk or severity of adverse effects can be increased when Imipramine is combined with Losartan.Approved
LovastatinThe metabolism of Imipramine can be decreased when combined with Lovastatin.Approved, Investigational
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Imipramine.Approved
LuliconazoleThe serum concentration of Imipramine can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Imipramine can be decreased when it is combined with Lumacaftor.Approved
LumefantrineImipramine may increase the QTc-prolonging activities of Lumefantrine.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Imipramine.Approved
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Imipramine.Approved, Vet Approved
ManidipineThe metabolism of Imipramine can be decreased when combined with Manidipine.Approved, Investigational
MannitolThe risk or severity of adverse effects can be increased when Imipramine is combined with Mannitol.Approved, Investigational
MaprotilineThe risk or severity of adverse effects can be increased when Imipramine is combined with Maprotiline.Approved
MebanazineMebanazine may increase the serotonergic activities of Imipramine.Withdrawn
MebicarThe risk or severity of adverse effects can be increased when Mebicar is combined with Imipramine.Experimental
MecamylamineThe risk or severity of adverse effects can be increased when Imipramine is combined with Mecamylamine.Approved
MeclizineThe risk or severity of adverse effects can be increased when Imipramine is combined with Meclizine.Approved
MedazepamThe risk or severity of adverse effects can be increased when Medazepam is combined with Imipramine.Experimental
MedetomidineThe risk or severity of adverse effects can be increased when Medetomidine is combined with Imipramine.Vet Approved
MelagatranThe serum concentration of Imipramine can be increased when it is combined with Melagatran.Experimental
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Imipramine.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Melperone is combined with Imipramine.Approved, Investigational
MephedroneImipramine may increase the stimulatory activities of Mephedrone.Investigational
MephentermineImipramine may increase the vasopressor activities of Mephentermine.Approved
MephenytoinThe metabolism of Mephenytoin can be decreased when combined with Imipramine.Investigational, Withdrawn
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Imipramine.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Imipramine.Approved, Illicit
MeptazinolThe risk or severity of adverse effects can be increased when Meptazinol is combined with Imipramine.Experimental
MequitazineThe metabolism of Mequitazine can be decreased when combined with Imipramine.Approved
MesoridazineThe metabolism of Mesoridazine can be decreased when combined with Imipramine.Approved, Investigational
MetaraminolImipramine may increase the vasopressor activities of Metaraminol.Approved, Investigational
MetaxaloneThe risk or severity of adverse effects can be increased when Imipramine is combined with Metaxalone.Approved
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Imipramine.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Imipramine.Approved, Illicit
MethamphetamineImipramine may decrease the antihypertensive activities of Methamphetamine.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Imipramine.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Imipramine.Illicit, Withdrawn
MethazolamideThe risk or severity of adverse effects can be increased when Imipramine is combined with Methazolamide.Approved
MethocarbamolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Imipramine.Approved, Vet Approved
MethohexitalThe metabolism of Imipramine can be increased when combined with Methohexital.Approved
MethotrimeprazineImipramine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxamineImipramine may increase the vasopressor activities of Methoxamine.Approved, Investigational
MethoxyfluraneThe metabolism of Methoxyflurane can be decreased when combined with Imipramine.Approved, Investigational, Vet Approved
MethoxyphenamineImipramine may increase the stimulatory activities of Methoxyphenamine.Experimental
MethsuximideThe risk or severity of adverse effects can be increased when Imipramine is combined with Methsuximide.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Imipramine is combined with Methyclothiazide.Approved
MethyldopaThe risk or severity of adverse effects can be increased when Imipramine is combined with Methyldopa.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Imipramine.Experimental
Methylene blueImipramine may increase the serotonergic activities of Methylene blue.Approved, Investigational
MethylphenidateThe risk or severity of adverse effects can be increased when Methylphenidate is combined with Imipramine.Approved, Investigational
MethylphenobarbitalThe metabolism of Imipramine can be increased when combined with Methylphenobarbital.Approved
MethyprylonThe metabolism of Methyprylon can be decreased when combined with Imipramine.Approved, Illicit, Withdrawn
MetipranololThe risk or severity of adverse effects can be increased when Imipramine is combined with Metipranolol.Approved
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Imipramine.Approved, Investigational
MetolazoneThe risk or severity of adverse effects can be increased when Imipramine is combined with Metolazone.Approved
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Imipramine.Approved, Investigational
MetyrosineImipramine may increase the sedative activities of Metyrosine.Approved
MexiletineThe metabolism of Imipramine can be decreased when combined with Mexiletine.Approved
MianserinThe metabolism of Mianserin can be decreased when combined with Imipramine.Approved, Investigational
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Imipramine.Approved, Illicit
MidodrineImipramine may increase the vasopressor activities of Midodrine.Approved
MidomafetamineImipramine may increase the stimulatory activities of Midomafetamine.Experimental, Illicit, Investigational
MidostaurinThe metabolism of Imipramine can be decreased when combined with Midostaurin.Approved
MifepristoneMifepristone may increase the QTc-prolonging activities of Imipramine.Approved, Investigational
MilnacipranThe risk or severity of adverse effects can be increased when Imipramine is combined with Milnacipran.Approved
MinaprineThe metabolism of Minaprine can be decreased when combined with Imipramine.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Imipramine.Approved, Investigational
MinoxidilThe risk or severity of adverse effects can be increased when Imipramine is combined with Minoxidil.Approved
MirabegronThe metabolism of Mirabegron can be decreased when combined with Imipramine.Approved
MirtazapineImipramine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MitotaneThe serum concentration of Imipramine can be decreased when it is combined with Mitotane.Approved
MMDAImipramine may increase the stimulatory activities of MMDA.Experimental, Illicit
MoclobemideThe risk or severity of adverse effects can be increased when Imipramine is combined with Moclobemide.Approved
ModafinilThe metabolism of Imipramine can be decreased when combined with Modafinil.Approved, Investigational
MoexiprilThe serum concentration of Imipramine can be increased when it is combined with Moexipril.Approved
MolindoneThe risk or severity of adverse effects can be increased when Molindone is combined with Imipramine.Approved
MoperoneThe risk or severity of adverse effects can be increased when Imipramine is combined with Moperone.Experimental
MorphineThe risk or severity of adverse effects can be increased when Imipramine is combined with Morphine.Approved, Investigational
MosapramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Mosapramine.Experimental
MoxifloxacinImipramine may increase the QTc-prolonging activities of Moxifloxacin.Approved, Investigational
MoxonidineThe therapeutic efficacy of Moxonidine can be decreased when used in combination with Imipramine.Approved, Investigational
N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-ProlineThe serum concentration of Imipramine can be increased when it is combined with N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-Proline.Experimental
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Imipramine.Approved, Investigational
NadololThe risk or severity of adverse effects can be increased when Imipramine is combined with Nadolol.Approved
NafamostatThe serum concentration of Imipramine can be increased when it is combined with Nafamostat.Approved, Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Imipramine.Approved
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Imipramine.Approved
NaphazolineImipramine may decrease the antihypertensive activities of Naphazoline.Approved
NaratriptanThe risk or severity of adverse effects can be increased when Imipramine is combined with Naratriptan.Approved, Investigational
NateglinideThe metabolism of Nateglinide can be decreased when combined with Imipramine.Approved, Investigational
NebivololThe serum concentration of Nebivolol can be increased when it is combined with Imipramine.Approved, Investigational
NefazodoneThe metabolism of Imipramine can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Imipramine can be decreased when combined with Nelfinavir.Approved
NesiritideThe risk or severity of adverse effects can be increased when Imipramine is combined with Nesiritide.Approved, Investigational
NetupitantThe serum concentration of Imipramine can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Imipramine can be increased when combined with Nevirapine.Approved
NialamideNialamide may increase the serotonergic activities of Imipramine.Withdrawn
NicardipineThe risk or severity of adverse effects can be increased when Imipramine is combined with Nicardipine.Approved
NicergolineThe metabolism of Nicergoline can be decreased when combined with Imipramine.Approved, Investigational
NicorandilImipramine may increase the hypotensive activities of Nicorandil.Approved, Investigational
NicotineThe metabolism of Nicotine can be decreased when combined with Imipramine.Approved
NifedipineThe risk or severity of adverse effects can be increased when Imipramine is combined with Nifedipine.Approved
NilotinibImipramine may increase the QTc-prolonging activities of Nilotinib.Approved, Investigational
NilvadipineThe risk or severity of adverse effects can be increased when Imipramine is combined with Nilvadipine.Approved, Investigational
NimodipineThe risk or severity of adverse effects can be increased when Imipramine is combined with Nimodipine.Approved
NisoldipineThe risk or severity of adverse effects can be increased when Imipramine is combined with Nisoldipine.Approved
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Imipramine.Approved
NitrendipineThe risk or severity of adverse effects can be increased when Imipramine is combined with Nitrendipine.Approved, Investigational
Nitric OxideThe risk or severity of adverse effects can be increased when Imipramine is combined with Nitric Oxide.Approved
NitroaspirinThe serum concentration of Imipramine can be increased when it is combined with Nitroaspirin.Investigational
NitrofuralThe metabolism of Nitrofural can be decreased when combined with Imipramine.Approved, Investigational, Vet Approved
NitroglycerinThe risk or severity of adverse effects can be increased when Imipramine is combined with Nitroglycerin.Approved, Investigational
NitroprussideThe risk or severity of adverse effects can be increased when Imipramine is combined with Nitroprusside.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Imipramine.Approved, Vet Approved
NorepinephrineImipramine may decrease the antihypertensive activities of Norepinephrine.Approved
NorfluraneThe risk or severity of adverse effects can be increased when Norflurane is combined with Imipramine.Investigational
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Imipramine.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Imipramine is combined with Nortriptyline.Approved
ObinutuzumabThe risk or severity of adverse effects can be increased when Imipramine is combined with Obinutuzumab.Approved
OctamoxinOctamoxin may increase the serotonergic activities of Imipramine.Withdrawn
OfloxacinImipramine may increase the QTc-prolonging activities of Ofloxacin.Approved
OlanzapineThe metabolism of Olanzapine can be decreased when combined with Imipramine.Approved, Investigational
OlaparibThe metabolism of Imipramine can be decreased when combined with Olaparib.Approved
OlmesartanThe risk or severity of adverse effects can be increased when Imipramine is combined with Olmesartan.Approved, Investigational
OlodaterolThe risk or severity of adverse effects can be increased when Imipramine is combined with Olodaterol.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Imipramine is combined with Olopatadine.Approved
OmapatrilatThe serum concentration of Imipramine can be increased when it is combined with Omapatrilat.Investigational
OmeprazoleThe metabolism of Imipramine can be decreased when combined with Omeprazole.Approved, Investigational, Vet Approved
OndansetronImipramine may increase the QTc-prolonging activities of Ondansetron.Approved
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Imipramine.Approved, Illicit
OrciprenalineThe risk or severity of adverse effects can be increased when Imipramine is combined with Orciprenaline.Approved
OrphenadrineImipramine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Osanetant is combined with Imipramine.Investigational
OsimertinibThe serum concentration of Imipramine can be increased when it is combined with Osimertinib.Approved
OtamixabanThe serum concentration of Imipramine can be increased when it is combined with Otamixaban.Investigational
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Imipramine.Approved
OxethazaineThe risk or severity of adverse effects can be increased when Oxethazaine is combined with Imipramine.Approved, Investigational
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Imipramine.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Imipramine.Approved
OxycodoneThe metabolism of Oxycodone can be decreased when combined with Imipramine.Approved, Illicit, Investigational
OxymetazolineImipramine may decrease the antihypertensive activities of Oxymetazoline.Approved
OxymorphoneThe metabolism of Oxymorphone can be decreased when combined with Imipramine.Approved, Investigational, Vet Approved
OxypertineThe risk or severity of adverse effects can be increased when Imipramine is combined with Oxypertine.Experimental
PaclitaxelThe risk or severity of adverse effects can be increased when Imipramine is combined with Paclitaxel.Approved, Vet Approved
PalbociclibThe serum concentration of Imipramine can be increased when it is combined with Palbociclib.Approved
PaliperidoneImipramine may decrease the antihypertensive activities of Paliperidone.Approved
PalonosetronPalonosetron may increase the serotonergic activities of Imipramine.Approved, Investigational
PanobinostatThe serum concentration of Imipramine can be increased when it is combined with Panobinostat.Approved, Investigational
PantoprazoleThe metabolism of Imipramine can be decreased when combined with Pantoprazole.Approved
PapaverineThe risk or severity of adverse effects can be increased when Imipramine is combined with Papaverine.Approved
ParaldehydeImipramine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved, Investigational
PargylinePargyline may increase the serotonergic activities of Imipramine.Approved
ParoxetineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Imipramine.Approved, Investigational
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Imipramine.Approved
Peginterferon alfa-2bThe serum concentration of Imipramine can be decreased when it is combined with Peginterferon alfa-2b.Approved
PenbutololThe risk or severity of adverse effects can be increased when Imipramine is combined with Penbutolol.Approved, Investigational
PenfluridolThe risk or severity of adverse effects can be increased when Penfluridol is combined with Imipramine.Experimental
PentamidineImipramine may increase the QTc-prolonging activities of Pentamidine.Approved
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Imipramine.Approved, Vet Approved
PentobarbitalThe metabolism of Imipramine can be increased when combined with Pentobarbital.Approved, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Imipramine.Approved
PerazineThe risk or severity of adverse effects can be increased when Perazine is combined with Imipramine.Investigational
PerflutrenImipramine may increase the QTc-prolonging activities of Perflutren.Approved
PergolideImipramine may decrease the antihypertensive activities of Pergolide.Approved, Investigational, Vet Approved, Withdrawn
PerhexilineThe metabolism of Perhexiline can be decreased when combined with Imipramine.Approved, Investigational
PerindoprilThe serum concentration of Imipramine can be increased when it is combined with Perindopril.Approved
PerospironeThe risk or severity of adverse effects can be increased when Perospirone is combined with Imipramine.Approved
PerphenazineThe metabolism of Perphenazine can be decreased when combined with Imipramine.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Imipramine.Approved
PhenacetinThe metabolism of Phenacetin can be decreased when combined with Imipramine.Withdrawn
PhenazocineThe risk or severity of adverse effects can be increased when Phenazocine is combined with Imipramine.Experimental
PhenelzineThe risk or severity of adverse effects can be increased when Imipramine is combined with Phenelzine.Approved
PhenforminThe metabolism of Phenformin can be decreased when combined with Imipramine.Approved, Investigational, Withdrawn
PhenibutThe risk or severity of adverse effects can be increased when Phenibut is combined with Imipramine.Experimental
PhenindioneImipramine may increase the anticoagulant activities of Phenindione.Approved, Investigational
PheniprazinePheniprazine may increase the serotonergic activities of Imipramine.Withdrawn
PhenobarbitalThe metabolism of Imipramine can be increased when combined with Phenobarbital.Approved
PhenoperidineThe risk or severity of adverse effects can be increased when Phenoperidine is combined with Imipramine.Experimental
PhenoxybenzamineThe risk or severity of adverse effects can be increased when Imipramine is combined with Phenoxybenzamine.Approved
PhenoxyethanolThe risk or severity of adverse effects can be increased when Phenoxyethanol is combined with Imipramine.Approved
PhenoxypropazinePhenoxypropazine may increase the serotonergic activities of Imipramine.Withdrawn
PhenprocoumonImipramine may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
PhentermineImipramine may increase the stimulatory activities of Phentermine.Approved, Illicit
PhentolamineThe risk or severity of adverse effects can be increased when Imipramine is combined with Phentolamine.Approved
PhenylephrineImipramine may increase the vasopressor activities of Phenylephrine.Approved
PhenylpropanolamineThe risk or severity of adverse effects can be increased when Imipramine is combined with Phenylpropanolamine.Approved, Vet Approved, Withdrawn
PhenytoinThe metabolism of Imipramine can be increased when combined with Phenytoin.Approved, Vet Approved
PhosphoramidonThe serum concentration of Imipramine can be increased when it is combined with Phosphoramidon.Experimental
PimozideImipramine may increase the QTc-prolonging activities of Pimozide.Approved
PindololThe metabolism of Pindolol can be decreased when combined with Imipramine.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Imipramine.Approved, Investigational
PiperazineThe metabolism of Piperazine can be decreased when combined with Imipramine.Approved, Vet Approved
PipotiazineThe metabolism of Pipotiazine can be decreased when combined with Imipramine.Approved, Investigational
PirbuterolThe risk or severity of adverse effects can be increased when Imipramine is combined with Pirbuterol.Approved
PiritramideThe risk or severity of adverse effects can be increased when Piritramide is combined with Imipramine.Investigational
PirlindolePirlindole may increase the serotonergic activities of Imipramine.Approved
PivhydrazinePivhydrazine may increase the serotonergic activities of Imipramine.Withdrawn
PizotifenThe risk or severity of adverse effects can be increased when Imipramine is combined with Pizotifen.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Imipramine is combined with Pomalidomide.Approved
PonatinibThe metabolism of Ponatinib can be decreased when combined with Imipramine.Approved
PosaconazoleThe metabolism of Imipramine can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PramipexoleImipramine may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Imipramine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Imipramine.Approved, Illicit
PrazosinThe risk or severity of adverse effects can be increased when Imipramine is combined with Prazosin.Approved
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Imipramine.Approved, Illicit, Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Imipramine.Approved
PrimaquineImipramine may increase the QTc-prolonging activities of Primaquine.Approved
PrimidoneThe metabolism of Imipramine can be increased when combined with Primidone.Approved, Vet Approved
PrinomastatThe serum concentration of Imipramine can be increased when it is combined with Prinomastat.Investigational
ProcainamideImipramine may increase the QTc-prolonging activities of Procainamide.Approved
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Imipramine.Approved, Investigational, Vet Approved
ProcarbazineThe risk or severity of adverse effects can be increased when Imipramine is combined with Procarbazine.Approved
ProcaterolThe risk or severity of adverse effects can be increased when Imipramine is combined with Procaterol.Approved, Investigational
ProchlorperazineThe metabolism of Prochlorperazine can be decreased when combined with Imipramine.Approved, Vet Approved
ProgesteroneThe metabolism of Progesterone can be decreased when combined with Imipramine.Approved, Vet Approved
PromazineImipramine may increase the QTc-prolonging activities of Promazine.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Imipramine is combined with Promethazine.Approved
PropafenoneThe serum concentration of Imipramine can be increased when it is combined with Propafenone.Approved
PropanididThe risk or severity of adverse effects can be increased when Propanidid is combined with Imipramine.Experimental
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Imipramine.Approved, Vet Approved
PropericiazineThe risk or severity of adverse effects can be increased when Imipramine is combined with Propericiazine.Approved
PropofolThe metabolism of Propofol can be decreased when combined with Imipramine.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Propoxycaine is combined with Imipramine.Approved
PropranololThe risk or severity of adverse effects can be increased when Imipramine is combined with Propranolol.Approved, Investigational
ProthipendylThe risk or severity of adverse effects can be increased when Imipramine is combined with Prothipendyl.Investigational
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Imipramine.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when Proxibarbal is combined with Imipramine.Experimental
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Imipramine.Approved
PSD502The risk or severity of adverse effects can be increased when PSD502 is combined with Imipramine.Investigational
PseudoephedrineImipramine may decrease the antihypertensive activities of Pseudoephedrine.Approved
QuazepamThe serum concentration of Imipramine can be increased when it is combined with Quazepam.Approved, Illicit
QuetiapineImipramine may increase the QTc-prolonging activities of Quetiapine.Approved
QuinaprilThe serum concentration of Imipramine can be increased when it is combined with Quinapril.Approved, Investigational
QuinidineImipramine may increase the QTc-prolonging activities of Quinidine.Approved
QuinineImipramine may increase the QTc-prolonging activities of Quinine.Approved
QuinisocaineThe risk or severity of adverse effects can be increased when Quinisocaine is combined with Imipramine.Experimental
RacecadotrilThe serum concentration of Imipramine can be increased when it is combined with Racecadotril.Investigational
RacloprideThe risk or severity of adverse effects can be increased when Raclopride is combined with Imipramine.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Imipramine is combined with Ramelteon.Approved, Investigational
RamiprilThe serum concentration of Imipramine can be increased when it is combined with Ramipril.Approved
RanitidineThe metabolism of Ranitidine can be decreased when combined with Imipramine.Approved
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Imipramine.Approved, Investigational
RasagilineThe risk or severity of adverse effects can be increased when Imipramine is combined with Rasagiline.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Imipramine.Approved
RemikirenThe serum concentration of Imipramine can be increased when it is combined with Remikiren.Approved
RemoxiprideThe metabolism of Remoxipride can be decreased when combined with Imipramine.Approved, Withdrawn
repinotanThe metabolism of repinotan can be decreased when combined with Imipramine.Investigational
ReserpineThe risk or severity of adverse effects can be increased when Imipramine is combined with Reserpine.Approved, Investigational
RifabutinThe metabolism of Imipramine can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Imipramine can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Imipramine can be increased when combined with Rifapentine.Approved
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Imipramine.Approved, Investigational
RiociguatThe risk or severity of adverse effects can be increased when Imipramine is combined with Riociguat.Approved
RisperidoneImipramine may increase the hypotensive activities of Risperidone.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Ritanserin is combined with Imipramine.Investigational
RitobegronImipramine may increase the stimulatory activities of Ritobegron.Investigational
RitodrineThe risk or severity of adverse effects can be increased when Imipramine is combined with Ritodrine.Approved, Investigational
RitonavirThe metabolism of Imipramine can be decreased when combined with Ritonavir.Approved, Investigational
RivaroxabanThe serum concentration of Imipramine can be increased when it is combined with Rivaroxaban.Approved
RizatriptanThe risk or severity of adverse effects can be increased when Imipramine is combined with Rizatriptan.Approved
RolapitantThe metabolism of Imipramine can be decreased when combined with Rolapitant.Approved
RomifidineThe risk or severity of adverse effects can be increased when Romifidine is combined with Imipramine.Vet Approved
RopiniroleImipramine may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe metabolism of Ropivacaine can be decreased when combined with Imipramine.Approved
RotigotineImipramine may increase the sedative activities of Rotigotine.Approved
RucaparibThe metabolism of Rucaparib can be decreased when combined with Imipramine.Approved, Investigational
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Imipramine.Approved
RupatadineThe metabolism of Rupatadine can be decreased when combined with Imipramine.Approved
S-3304The serum concentration of Imipramine can be increased when it is combined with S-3304.Investigational
SacubitrilThe risk or severity of adverse effects can be increased when Imipramine is combined with Sacubitril.Approved
SafrazineSafrazine may increase the serotonergic activities of Imipramine.Withdrawn
SalbutamolThe risk or severity of adverse effects can be increased when Imipramine is combined with Salbutamol.Approved, Vet Approved
SalmeterolThe risk or severity of adverse effects can be increased when Imipramine is combined with Salmeterol.Approved
SaquinavirThe metabolism of Imipramine can be decreased when combined with Saquinavir.Approved, Investigational
SaxagliptinThe serum concentration of Imipramine can be increased when it is combined with Saxagliptin.Approved
ScopolamineThe risk or severity of adverse effects can be increased when Imipramine is combined with Scopolamine.Approved
SecobarbitalThe metabolism of Imipramine can be increased when combined with Secobarbital.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Imipramine is combined with Selegiline.Approved, Investigational, Vet Approved
SepranoloneThe risk or severity of adverse effects can be increased when Sepranolone is combined with Imipramine.Investigational
SertindoleThe metabolism of Sertindole can be decreased when combined with Imipramine.Approved, Investigational, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Sertraline is combined with Imipramine.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Imipramine.Approved, Vet Approved
SildenafilThe metabolism of Imipramine can be decreased when combined with Sildenafil.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Imipramine.Approved
SiltuximabThe serum concentration of Imipramine can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Imipramine can be increased when it is combined with Simeprevir.Approved
SimvastatinThe metabolism of Simvastatin can be decreased when combined with Imipramine.Approved
SitagliptinThe serum concentration of Imipramine can be increased when it is combined with Sitagliptin.Approved, Investigational
SivelestatThe serum concentration of Imipramine can be increased when it is combined with Sivelestat.Investigational
Sodium NitriteThe risk or severity of adverse effects can be increased when Imipramine is combined with Sodium Nitrite.Approved
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Imipramine.Approved
Sodium phosphateThe risk or severity of adverse effects can be increased when Imipramine is combined with Sodium phosphate.Approved
SorafenibThe metabolism of Imipramine can be decreased when combined with Sorafenib.Approved, Investigational
SotalolImipramine may increase the QTc-prolonging activities of Sotalol.Approved
SparteineThe metabolism of Sparteine can be decreased when combined with Imipramine.Experimental
SpiraprilThe serum concentration of Imipramine can be increased when it is combined with Spirapril.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Imipramine is combined with Spironolactone.Approved
St. John's WortThe metabolism of Imipramine can be increased when combined with St. John's Wort.Investigational, Nutraceutical
StiripentolThe serum concentration of Imipramine can be increased when it is combined with Stiripentol.Approved
StreptokinaseThe risk or severity of adverse effects can be increased when Imipramine is combined with Streptokinase.Approved, Investigational
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Imipramine.Approved, Investigational
SulfisoxazoleImipramine may increase the QTc-prolonging activities of Sulfisoxazole.Approved, Vet Approved
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Imipramine.Approved, Investigational
SultoprideThe risk or severity of adverse effects can be increased when Sultopride is combined with Imipramine.Experimental
SumatriptanThe risk or severity of adverse effects can be increased when Imipramine is combined with Sumatriptan.Approved, Investigational
SuvorexantImipramine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TamoxifenThe serum concentration of the active metabolites of Tamoxifen can be reduced when Tamoxifen is used in combination with Imipramine resulting in a loss in efficacy.Approved
TamsulosinThe metabolism of Tamsulosin can be decreased when combined with Imipramine.Approved, Investigational
TandospironeThe risk or severity of adverse effects can be increased when Tandospirone is combined with Imipramine.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Imipramine.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Imipramine is combined with Tasimelteon.Approved
Tedizolid PhosphateTedizolid Phosphate may increase the serotonergic activities of Imipramine.Approved
TegaserodThe metabolism of Tegaserod can be decreased when combined with Imipramine.Investigational, Withdrawn
TelaprevirThe metabolism of Imipramine can be decreased when combined with Telaprevir.Approved, Withdrawn
TelavancinImipramine may increase the QTc-prolonging activities of Telavancin.Approved
TelithromycinThe metabolism of Imipramine can be decreased when combined with Telithromycin.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Imipramine is combined with Telmisartan.Approved, Investigational
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Imipramine.Approved
TemocaprilThe serum concentration of Imipramine can be increased when it is combined with Temocapril.Experimental, Investigational
Tenofovir disoproxilThe metabolism of Imipramine can be decreased when combined with Tenofovir disoproxil.Approved, Investigational
TerazosinThe risk or severity of adverse effects can be increased when Imipramine is combined with Terazosin.Approved
TerbinafineThe metabolism of Imipramine can be decreased when combined with Terbinafine.Approved, Investigational, Vet Approved
TerbutalineThe risk or severity of adverse effects can be increased when Imipramine is combined with Terbutaline.Approved
TerfenadineThe metabolism of Terfenadine can be decreased when combined with Imipramine.Withdrawn
TeriflunomideThe serum concentration of Imipramine can be decreased when it is combined with Teriflunomide.Approved
TesmilifeneThe metabolism of Tesmilifene can be decreased when combined with Imipramine.Investigational
TetrabenazineImipramine may increase the QTc-prolonging activities of Tetrabenazine.Approved
TetracaineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Imipramine.Approved, Vet Approved
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Imipramine.Investigational
TetrodotoxinThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Imipramine.Investigational
ThalidomideImipramine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
TheophyllineThe metabolism of Imipramine can be decreased when combined with Theophylline.Approved
ThiamylalThe metabolism of Imipramine can be increased when combined with Thiamylal.Approved, Vet Approved
ThiopentalThe metabolism of Imipramine can be increased when combined with Thiopental.Approved, Vet Approved
ThiopropazateThe risk or severity of adverse effects can be increased when Imipramine is combined with Thiopropazate.Experimental
ThioproperazineThe risk or severity of adverse effects can be increased when Imipramine is combined with Thioproperazine.Approved
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Imipramine.Approved, Withdrawn
ThiorphanThe serum concentration of Imipramine can be increased when it is combined with Thiorphan.Experimental
ThiotepaThe metabolism of Imipramine can be decreased when combined with Thiotepa.Approved
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Imipramine.Approved
Thyroid, porcineThyroid, porcine may increase the arrhythmogenic activities of Imipramine.Approved
TiagabineThe risk or severity of adverse effects can be increased when Imipramine is combined with Tiagabine.Approved
TiaprideThe risk or severity of adverse effects can be increased when Tiapride is combined with Imipramine.Approved, Investigational
TiclopidineThe metabolism of Imipramine can be decreased when combined with Ticlopidine.Approved
TiletamineThe risk or severity of adverse effects can be increased when Tiletamine is combined with Imipramine.Vet Approved
TilidineThe risk or severity of adverse effects can be increased when Tilidine is combined with Imipramine.Experimental
TimololThe risk or severity of adverse effects can be increased when Imipramine is combined with Timolol.Approved
TioclomarolImipramine may increase the anticoagulant activities of Tioclomarol.Experimental
TiotropiumThe metabolism of Tiotropium can be decreased when combined with Imipramine.Approved
TipranavirThe metabolism of Imipramine can be decreased when combined with Tipranavir.Approved, Investigational
TizanidineThe serum concentration of Tizanidine can be increased when it is combined with Imipramine.Approved
TocilizumabThe serum concentration of Imipramine can be decreased when it is combined with Tocilizumab.Approved
TolazolineThe risk or severity of adverse effects can be increased when Imipramine is combined with Tolazoline.Approved, Vet Approved
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Imipramine.Approved, Withdrawn
ToloxatoneToloxatone may increase the serotonergic activities of Imipramine.Approved
TolterodineThe metabolism of Tolterodine can be decreased when combined with Imipramine.Approved, Investigational
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Imipramine.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Imipramine.Approved, Investigational
TorasemideThe risk or severity of adverse effects can be increased when Imipramine is combined with Torasemide.Approved
ToremifeneImipramine may increase the QTc-prolonging activities of Toremifene.Approved, Investigational
TrabectedinThe metabolism of Trabectedin can be decreased when combined with Imipramine.Approved, Investigational
TramadolImipramine may increase the neuroexcitatory activities of Tramadol.Approved, Investigational
TrandolaprilThe serum concentration of Imipramine can be increased when it is combined with Trandolapril.Approved
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Imipramine.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Imipramine is combined with Tranylcypromine.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Imipramine.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Imipramine is combined with Tretinoin.Approved, Investigational, Nutraceutical
TriamtereneThe risk or severity of adverse effects can be increased when Imipramine is combined with Triamterene.Approved
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Imipramine.Approved
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Tricaine methanesulfonate is combined with Imipramine.Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Trichloroethylene is combined with Imipramine.Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Imipramine.Approved
TrifluperidolThe risk or severity of adverse effects can be increased when Trifluperidol is combined with Imipramine.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Imipramine.Approved, Vet Approved
TrimipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Trimipramine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Imipramine.Approved
TropisetronTropisetron may increase the serotonergic activities of Imipramine.Approved, Investigational
UbenimexThe serum concentration of Imipramine can be increased when it is combined with Ubenimex.Experimental, Investigational
UlinastatinThe serum concentration of Imipramine can be increased when it is combined with Ulinastatin.Investigational
UmeclidiniumThe metabolism of Umeclidinium can be decreased when combined with Imipramine.Approved
ValbenazineThe metabolism of Valbenazine can be decreased when combined with Imipramine.Approved, Investigational
Valproic AcidThe serum concentration of Imipramine can be increased when it is combined with Valproic Acid.Approved, Investigational
ValsartanThe risk or severity of adverse effects can be increased when Imipramine is combined with Valsartan.Approved, Investigational
VandetanibImipramine may increase the QTc-prolonging activities of Vandetanib.Approved
VemurafenibThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Imipramine.Approved
VenlafaxineThe risk or severity of adverse effects can be increased when Venlafaxine is combined with Imipramine.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Veralipride is combined with Imipramine.Experimental
VerapamilThe metabolism of Imipramine can be decreased when combined with Verapamil.Approved
VernakalantThe metabolism of Vernakalant can be decreased when combined with Imipramine.Approved, Investigational
VigabatrinThe risk or severity of adverse effects can be increased when Imipramine is combined with Vigabatrin.Approved
VilanterolThe risk or severity of adverse effects can be increased when Imipramine is combined with Vilanterol.Approved
VilazodoneThe risk or severity of adverse effects can be increased when Vilazodone is combined with Imipramine.Approved
VildagliptinThe serum concentration of Imipramine can be increased when it is combined with Vildagliptin.Approved, Investigational
VinblastineThe metabolism of Vinblastine can be decreased when combined with Imipramine.Approved
VincristineThe serum concentration of Vincristine can be increased when it is combined with Imipramine.Approved, Investigational
VinorelbineThe metabolism of Vinorelbine can be decreased when combined with Imipramine.Approved, Investigational
Vinyl etherThe risk or severity of adverse effects can be increased when Vinyl ether is combined with Imipramine.Experimental
VoriconazoleThe metabolism of Imipramine can be decreased when combined with Voriconazole.Approved, Investigational
VortioxetineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Imipramine.Approved
WarfarinImipramine may increase the anticoagulant activities of Warfarin.Approved
XenonThe risk or severity of adverse effects can be increased when Xenon is combined with Imipramine.Experimental
XimelagatranThe serum concentration of Imipramine can be increased when it is combined with Ximelagatran.Approved, Investigational, Withdrawn
XylazineThe risk or severity of adverse effects can be increased when Xylazine is combined with Imipramine.Vet Approved
XylometazolineImipramine may decrease the antihypertensive activities of Xylometazoline.Approved
YohimbineThe serum concentration of Yohimbine can be increased when it is combined with Imipramine.Approved, Vet Approved
Z-Val-Ala-Asp fluoromethyl ketoneThe serum concentration of Imipramine can be increased when it is combined with Z-Val-Ala-Asp fluoromethyl ketone.Experimental
ZalcitabineThe metabolism of Zalcitabine can be decreased when combined with Imipramine.Approved, Investigational
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Imipramine.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Imipramine is combined with Ziconotide.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Imipramine is combined with Zimelidine.Withdrawn
ZiprasidoneImipramine may increase the QTc-prolonging activities of Ziprasidone.Approved
ZofenoprilThe serum concentration of Imipramine can be increased when it is combined with Zofenopril.Experimental
ZolazepamThe risk or severity of adverse effects can be increased when Zolazepam is combined with Imipramine.Vet Approved
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Imipramine.Approved, Investigational
ZolpidemImipramine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Imipramine is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Imipramine.Approved
ZotepineThe risk or severity of adverse effects can be increased when Zotepine is combined with Imipramine.Approved, Investigational
ZucapsaicinThe metabolism of Imipramine can be decreased when combined with Zucapsaicin.Approved
ZuclopenthixolImipramine may increase the QTc-prolonging activities of Zuclopenthixol.Approved, Investigational
Food Interactions
  • Avoid alcohol.
  • Avoid excessive quantities of coffee or tea (caffeine).
  • Avoid St.John's Wort.
  • Do not take fibers at the same time.
  • Take with food.

References

Synthesis Reference

U.S. Patent 2,554,736.

General References
Not Available
External Links
Human Metabolome Database
HMDB01848
KEGG Compound
C07049
PubChem Compound
3696
PubChem Substance
46507351
ChemSpider
3568
BindingDB
50010859
ChEBI
47499
ChEMBL
CHEMBL11
Therapeutic Targets Database
DAP001154
PharmGKB
PA449969
IUPHAR
357
Guide to Pharmacology
GtP Drug Page
HET
IXX
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
PDRhealth
PDRhealth Drug Page
Wikipedia
Imipramine
ATC Codes
N06AA02 — Imipramine
AHFS Codes
  • 28:16.04.28 — Tricyclics and Other Norepinephrine-reuptake Inhibitors
PDB Entries
2q72
FDA label
Download (152 KB)
MSDS
Download (73.6 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedBasic ScienceIncontinence, Fecal / Urinary Incontinence,Stress1
1CompletedTreatmentDepression1
2CompletedTreatmentArrythmias / Cardiovascular Disease (CVD) / Heart Diseases / Ventricular Arrythmias1
2CompletedTreatmentDepression1
2CompletedTreatmentSomatization Disorder / Somatoform Disorders1
3CompletedBasic ScienceLow Back Pain (LBP)1
3CompletedPreventionArrythmias / Cardiovascular Disease (CVD) / Heart Arrest / Heart Diseases / Myocardial Infarction (MI) / Severe ventricular arrhythmias1
3CompletedTreatmentArrythmias / Cardiovascular Disease (CVD) / Death, Sudden,Cardiac / Heart Diseases / Severe ventricular arrhythmias / Ventricular Arrythmias / Ventricular Tachycardia (VT)1
3CompletedTreatmentFunctional Gastrointestinal Disorders / Indigestion1
3CompletedTreatmentGastroesophageal Reflux Disease1
3CompletedTreatmentThoracic Pain1
3TerminatedTreatmentAnxiety Disorders / Dementias / Depression / Psychosomatic Disorders / Schizophrenic Disorders1
4CompletedTreatmentDepression1
4CompletedTreatmentDepressive Disorder NOS / Dysthymic Disorder / Major Depressive Disorder (MDD)1
4CompletedTreatmentDysthymic Disorder / Major Depressive Disorder (MDD)2
4Unknown StatusTreatmentPolyneuropathies1
Not AvailableCompletedBasic ScienceUrethral Sphincter Activity1
Not AvailableCompletedDiagnosticHealthy Volunteers1
Not AvailableCompletedTreatmentDepression1
Not AvailableCompletedTreatmentPanic Disorders1
Not AvailableNot Yet RecruitingTreatmentCancer, Breast1
Not AvailableUnknown StatusTreatmentTreatment Resistant Depression (TRD)1

Pharmacoeconomics

Manufacturers
  • Novartis pharmaceuticals corp
  • Actavis totowa llc
  • Lederle laboratories div american cyanamid co
  • Lupin ltd
  • Mutual pharmaceutical co inc
  • Par pharmaceutical inc
  • Roxane laboratories inc
  • Sandoz inc
  • Teva pharmaceuticals usa inc
  • Usl pharma inc
  • Vangard laboratories inc div midway medical co
  • Watson laboratories inc
  • West ward pharmaceutical corp
  • Abbott laboratories pharmaceutical products div
  • Alra laboratories inc
  • Sanofi aventis us llc
  • Tyco healthcare group lp
  • Odyssey pharmaceuticals inc
Packagers
Dosage forms
FormRouteStrength
TabletOral10 mg
TabletOral25 mg
TabletOral50 mg
TabletOral75 mg
TabletOral10 mg/1
TabletOral25 mg/1
TabletOral50 mg/1
Tablet, film coatedOral10 mg/1
Tablet, film coatedOral25 mg/1
Tablet, film coatedOral50 mg/1
Tablet, sugar coatedOral10 mg/1
Tablet, sugar coatedOral25 mg/1
Tablet, sugar coatedOral50 mg/1
CapsuleOral100 mg/1
CapsuleOral125 mg/1
CapsuleOral150 mg/1
CapsuleOral75 mg/1
Prices
Unit descriptionCostUnit
Tofranil-PM 30 125 mg capsule Bottle588.33USD bottle
Tofranil-PM 30 150 mg capsule Bottle588.33USD bottle
Tofranil-PM 30 75 mg capsule Bottle588.33USD bottle
Tofranil 30 50 mg tablet Bottle185.09USD bottle
Trimipramine maleate powder51.0USD g
Tofranil-pm 100 mg capsule19.23USD capsule
Tofranil-pm 150 mg capsule18.86USD capsule
Tofranil-pm 75 mg capsule18.86USD capsule
Tofranil-pm 125 mg capsule18.68USD capsule
Imipramine pamoate 75 mg capsule16.35USD capsule
Imipramine pamoate 100 mg capsule15.17USD capsule
Imipramine pamoate 125 mg capsule15.17USD capsule
Imipramine pamoate 150 mg capsule15.17USD capsule
Tofranil 50 mg tablet6.64USD tablet
Surmontil 100 mg capsule5.92USD capsule
Tofranil 25 mg tablet4.97USD tablet
Tofranil 10 mg tablet4.73USD tablet
Surmontil 50 mg capsule4.07USD capsule
Trimipramine Maleate 50 mg capsule3.27USD capsule
Trimipramine 50 mg capsule3.14USD capsule
Surmontil 25 mg capsule2.49USD capsule
Cenestin 0.3 mg tablet2.21USD tablet
Cenestin 0.45 mg tablet2.21USD tablet
Cenestin 0.625 mg tablet2.21USD tablet
Cenestin 0.9 mg tablet2.21USD tablet
Cenestin 1.25 mg tablet2.21USD tablet
Trimipramine 25 mg capsule1.92USD capsule
Apo-Trimip 100 mg Tablet0.97USD tablet
Imipramine hcl powder0.77USD g
Apo-Trimip 75 mg Capsule0.77USD capsule
Apo-Imipramine 75 mg Tablet0.58USD tablet
Tofranil 50 mg Tablet0.57USD tablet
Apo-Trimip 50 mg Tablet0.57USD tablet
Imipramine hcl 10 mg tablet0.46USD tablet
Imipramine hcl 50 mg tablet0.44USD tablet
Apo-Imipramine 50 mg Tablet0.4USD tablet
Imipramine hcl 25 mg tablet0.35USD tablet
Apo-Trimip 25 mg Tablet0.29USD tablet
Apo-Imipramine 25 mg Tablet0.25USD tablet
Apo-Trimip 12.5 mg Tablet0.23USD tablet
Apo-Imipramine 10 mg Tablet0.14USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)174-175U.S. Patent 2,554,736.
boiling point (°C)160 °C at 1.00E-01 mm HgPhysProp
water solubility18.2 mg/L (at 24 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP4.80HANSCH,C ET AL. (1995)
logS-4.19ADME Research, USCD
Caco2 permeability-4.85ADME Research, USCD
pKa9.4SANGSTER (1994)
Predicted Properties
PropertyValueSource
Water Solubility0.0664 mg/mLALOGPS
logP4.53ALOGPS
logP4.28ChemAxon
logS-3.6ALOGPS
pKa (Strongest Basic)9.2ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area6.48 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity90.61 m3·mol-1ChemAxon
Polarizability33.39 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9822
Blood Brain Barrier+0.9865
Caco-2 permeable+0.8867
P-glycoprotein substrateSubstrate0.7684
P-glycoprotein inhibitor IInhibitor0.8662
P-glycoprotein inhibitor IIInhibitor0.6205
Renal organic cation transporterInhibitor0.8541
CYP450 2C9 substrateNon-substrate0.7799
CYP450 2D6 substrateSubstrate0.9532
CYP450 3A4 substrateSubstrate0.6718
CYP450 1A2 substrateNon-inhibitor0.7583
CYP450 2C9 inhibitorNon-inhibitor0.9089
CYP450 2D6 inhibitorInhibitor0.9017
CYP450 2C19 inhibitorNon-inhibitor0.9304
CYP450 3A4 inhibitorNon-inhibitor0.8309
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8399
Ames testNon AMES toxic0.9132
CarcinogenicityNon-carcinogens0.9329
BiodegradationNot ready biodegradable0.9819
Rat acute toxicity3.0187 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9172
hERG inhibition (predictor II)Inhibitor0.7771
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Download (10.2 KB)
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
GC-MS Spectrum - EI-BGC-MSsplash10-0019-7490000000-3fb4d40b6a219f088ec8
Mass Spectrum (Electron Ionization)MSsplash10-0543-8890000000-6cf8e84f007ce7c750f2
MS/MS Spectrum - Quattro_QQQ 10V, PositiveLC-MS/MSsplash10-000i-9000000000-55d924fd00e5b357ce9e
MS/MS Spectrum - Quattro_QQQ 25V, PositiveLC-MS/MSsplash10-000i-9000000000-eb3c0ecdffc5d9d95e33
MS/MS Spectrum - Quattro_QQQ 40V, PositiveLC-MS/MSsplash10-0ab9-9432000000-033c51459b692622ee7d
MS/MS Spectrum - EI-B (Unknown) , PositiveLC-MS/MSsplash10-0019-7490000000-bb99ef31a755d9f6ba14
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-052r-9010000000-961429188e57c1480db8
1H NMR Spectrum1D NMRNot Applicable
[1H,13C] 2D NMR Spectrum2D NMRNot Applicable

Taxonomy

Description
This compound belongs to the class of organic compounds known as dibenzazepines. These are compounds with two benzene rings connected by an azepine ring. Azepine is an unsaturated seven-member heterocycle with one nitrogen atom replacing a carbon atom.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Benzazepines
Sub Class
Dibenzazepines
Direct Parent
Dibenzazepines
Alternative Parents
Alkyldiarylamines / Azepines / Benzenoids / Trialkylamines / Azacyclic compounds / Organopnictogen compounds / Hydrocarbon derivatives
Substituents
Dibenzazepine / Alkyldiarylamine / Tertiary aliphatic/aromatic amine / Azepine / Benzenoid / Tertiary aliphatic amine / Tertiary amine / Azacycle / Organic nitrogen compound / Organopnictogen compound
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
dibenzoazepine (CHEBI:47499) / a small molecule (CPD-11438)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Norepinephrine:sodium symporter activity
Specific Function
Amine transporter. Terminates the action of noradrenaline by its high affinity sodium-dependent reuptake into presynaptic terminals.
Gene Name
SLC6A2
Uniprot ID
P23975
Uniprot Name
Sodium-dependent noradrenaline transporter
Molecular Weight
69331.42 Da
References
  1. Mitchell HA, Ahern TH, Liles LC, Javors MA, Weinshenker D: The effects of norepinephrine transporter inactivation on locomotor activity in mice. Biol Psychiatry. 2006 Nov 15;60(10):1046-52. Epub 2006 Aug 7. [PubMed:16893531]
  2. Dziedzicka-Wasylewska M, Faron-Gorecka A, Kusmider M, Drozdowska E, Rogoz Z, Siwanowicz J, Caron MG, Bonisch H: Effect of antidepressant drugs in mice lacking the norepinephrine transporter. Neuropsychopharmacology. 2006 Nov;31(11):2424-32. Epub 2006 Mar 22. [PubMed:16554743]
  3. Anton M, Wagner B, Haubner R, Bodenstein C, Essien BE, Bonisch H, Schwaiger M, Gansbacher B, Weber WA: Use of the norepinephrine transporter as a reporter gene for non-invasive imaging of genetically modified cells. J Gene Med. 2004 Jan;6(1):119-26. [PubMed:14716684]
  4. Kantor L, Hewlett GH, Park YH, Richardson-Burns SM, Mellon MJ, Gnegy ME: Protein kinase C and intracellular calcium are required for amphetamine-mediated dopamine release via the norepinephrine transporter in undifferentiated PC12 cells. J Pharmacol Exp Ther. 2001 Jun;297(3):1016-24. [PubMed:11356924]
  5. Tatsumi M, Jansen K, Blakely RD, Richelson E: Pharmacological profile of neuroleptics at human monoamine transporters. Eur J Pharmacol. 1999 Mar 5;368(2-3):277-83. [PubMed:10193665]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Serotonin:sodium symporter activity
Specific Function
Serotonin transporter whose primary function in the central nervous system involves the regulation of serotonergic signaling via transport of serotonin molecules from the synaptic cleft back into t...
Gene Name
SLC6A4
Uniprot ID
P31645
Uniprot Name
Sodium-dependent serotonin transporter
Molecular Weight
70324.165 Da
References
  1. Leboyer M, Quintin P, Manivet P, Varoquaux O, Allilaire JF, Launay JM: Decreased serotonin transporter binding in unaffected relatives of manic depressive patients. Biol Psychiatry. 1999 Dec 15;46(12):1703-6. [PubMed:10624553]
  2. Scholze P, Zwach J, Kattinger A, Pifl C, Singer EA, Sitte HH: Transporter-mediated release: a superfusion study on human embryonic kidney cells stably expressing the human serotonin transporter. J Pharmacol Exp Ther. 2000 Jun;293(3):870-8. [PubMed:10869387]
  3. Quintin P, Benkelfat C, Launay JM, Arnulf I, Pointereau-Bellenger A, Barbault S, Alvarez JC, Varoquaux O, Perez-Diaz F, Jouvent R, Leboyer M: Clinical and neurochemical effect of acute tryptophan depletion in unaffected relatives of patients with bipolar affective disorder. Biol Psychiatry. 2001 Aug 1;50(3):184-90. [PubMed:11513817]
  4. Goulet M, Miller GM, Bendor J, Liu S, Meltzer PC, Madras BK: Non-amines, drugs without an amine nitrogen, potently block serotonin transport: novel antidepressant candidates? Synapse. 2001 Dec 1;42(3):129-40. [PubMed:11746710]
  5. Barkan T, Gurwitz D, Levy G, Weizman A, Rehavi M: Biochemical and pharmacological characterization of the serotonin transporter in human peripheral blood lymphocytes. Eur Neuropsychopharmacol. 2004 May;14(3):237-43. [PubMed:15056483]
  6. Schloss P, Betz H: Heterogeneity of antidepressant binding sites on the recombinant rat serotonin transporter SERT1. Biochemistry. 1995 Oct 3;34(39):12590-5. [PubMed:7548008]
  7. Tatsumi M, Groshan K, Blakely RD, Richelson E: Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997 Dec 11;340(2-3):249-58. [PubMed:9537821]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Virus receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including mescaline, psilocybin, 1-(2,5-dimethoxy-4-iodop...
Gene Name
HTR2A
Uniprot ID
P28223
Uniprot Name
5-hydroxytryptamine receptor 2A
Molecular Weight
52602.58 Da
References
  1. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217]
  2. Zanoveli JM, Nogueira RL, Zangrossi H Jr: Chronic imipramine treatment sensitizes 5-HT1A and 5-HT 2 A receptors in the dorsal periaqueductal gray matter: evidence from the elevated T-maze test of anxiety. Behav Pharmacol. 2005 Nov;16(7):543-52. [PubMed:16170231]
Details
4. Histamine H1 receptor
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Antagonist
General Function
Histamine receptor activity
Specific Function
In peripheral tissues, the H1 subclass of histamine receptors mediates the contraction of smooth muscles, increase in capillary permeability due to contraction of terminal venules, and catecholamin...
Gene Name
HRH1
Uniprot ID
P35367
Uniprot Name
Histamine H1 receptor
Molecular Weight
55783.61 Da
References
  1. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217]
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Antagonist
General Function
Protein heterodimerization activity
Specific Function
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) prot...
Gene Name
ADRA1A
Uniprot ID
P35348
Uniprot Name
Alpha-1A adrenergic receptor
Molecular Weight
51486.005 Da
References
  1. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217]
  2. Nojimoto FD, Mueller A, Hebeler-Barbosa F, Akinaga J, Lima V, Kiguti LR, Pupo AS: The tricyclic antidepressants amitriptyline, nortriptyline and imipramine are weak antagonists of human and rat alpha1B-adrenoceptors. Neuropharmacology. 2010 Jul-Aug;59(1-2):49-57. doi: 10.1016/j.neuropharm.2010.03.015. Epub 2010 Apr 2. [PubMed:20363235]
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Antagonist
General Function
Alpha1-adrenergic receptor activity
Specific Function
This alpha-adrenergic receptor mediates its effect through the influx of extracellular calcium.
Gene Name
ADRA1D
Uniprot ID
P25100
Uniprot Name
Alpha-1D adrenergic receptor
Molecular Weight
60462.205 Da
References
  1. Nojimoto FD, Mueller A, Hebeler-Barbosa F, Akinaga J, Lima V, Kiguti LR, Pupo AS: The tricyclic antidepressants amitriptyline, nortriptyline and imipramine are weak antagonists of human and rat alpha1B-adrenoceptors. Neuropharmacology. 2010 Jul-Aug;59(1-2):49-57. doi: 10.1016/j.neuropharm.2010.03.015. Epub 2010 Apr 2. [PubMed:20363235]
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Antagonist
General Function
Phosphatidylinositol phospholipase c activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
Gene Name
CHRM1
Uniprot ID
P11229
Uniprot Name
Muscarinic acetylcholine receptor M1
Molecular Weight
51420.375 Da
References
  1. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217]
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Antagonist
General Function
G-protein coupled acetylcholine receptor activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
Gene Name
CHRM2
Uniprot ID
P08172
Uniprot Name
Muscarinic acetylcholine receptor M2
Molecular Weight
51714.605 Da
References
  1. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217]
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Antagonist
General Function
Receptor activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
Gene Name
CHRM3
Uniprot ID
P20309
Uniprot Name
Muscarinic acetylcholine receptor M3
Molecular Weight
66127.445 Da
References
  1. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217]
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Antagonist
General Function
Guanyl-nucleotide exchange factor activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
Gene Name
CHRM4
Uniprot ID
P08173
Uniprot Name
Muscarinic acetylcholine receptor M4
Molecular Weight
53048.65 Da
References
  1. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217]
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Antagonist
General Function
Phosphatidylinositol phospholipase c activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
Gene Name
CHRM5
Uniprot ID
P08912
Uniprot Name
Muscarinic acetylcholine receptor M5
Molecular Weight
60073.205 Da
References
  1. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217]
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Inhibitor
General Function
Voltage-gated potassium channel activity
Specific Function
Voltage-gated potassium channel that mediates transmembrane potassium transport in excitable membranes, primarily in the brain. Mediates the major part of the dendritic A-type current I(SA) in brai...
Gene Name
KCND2
Uniprot ID
Q9NZV8
Uniprot Name
Potassium voltage-gated channel subfamily D member 2
Molecular Weight
70535.825 Da
References
  1. Casis O, Sanchez-Chapula JA: Disopyramide, imipramine, and amitriptyline bind to a common site on the transient outward K+ channel. J Cardiovasc Pharmacol. 1998 Oct;32(4):521-6. [PubMed:9781919]
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Inhibitor
General Function
Metal ion binding
Specific Function
Pore-forming (alpha) subunit of voltage-gated rapidly inactivating A-type potassium channels. May contribute to I(To) current in heart and I(Sa) current in neurons. Channel properties are modulated...
Gene Name
KCND3
Uniprot ID
Q9UK17
Uniprot Name
Potassium voltage-gated channel subfamily D member 3
Molecular Weight
73450.53 Da
References
  1. Casis O, Sanchez-Chapula JA: Disopyramide, imipramine, and amitriptyline bind to a common site on the transient outward K+ channel. J Cardiovasc Pharmacol. 1998 Oct;32(4):521-6. [PubMed:9781919]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
Binder
General Function
Serotonin receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including ergot alkaloid derivatives, 1-2,5,-dimethoxy-4-...
Gene Name
HTR2C
Uniprot ID
P28335
Uniprot Name
5-hydroxytryptamine receptor 2C
Molecular Weight
51820.705 Da
References
  1. Palvimaki EP, Roth BL, Majasuo H, Laakso A, Kuoppamaki M, Syvalahti E, Hietala J: Interactions of selective serotonin reuptake inhibitors with the serotonin 5-HT2c receptor. Psychopharmacology (Berl). 1996 Aug;126(3):234-40. [PubMed:8876023]
  2. Roth BL: Multiple serotonin receptors: clinical and experimental aspects. Ann Clin Psychiatry. 1994 Jun;6(2):67-78. [PubMed:7804391]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Protein heterodimerization activity
Specific Function
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) prot...
Gene Name
ADRA1B
Uniprot ID
P35368
Uniprot Name
Alpha-1B adrenergic receptor
Molecular Weight
56835.375 Da
References
  1. Nojimoto FD, Mueller A, Hebeler-Barbosa F, Akinaga J, Lima V, Kiguti LR, Pupo AS: The tricyclic antidepressants amitriptyline, nortriptyline and imipramine are weak antagonists of human and rat alpha1B-adrenoceptors. Neuropharmacology. 2010 Jul-Aug;59(1-2):49-57. doi: 10.1016/j.neuropharm.2010.03.015. Epub 2010 Apr 2. [PubMed:20363235]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Serotonin receptor activity
Specific Function
This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. The activity of this receptor ...
Gene Name
HTR7
Uniprot ID
P34969
Uniprot Name
5-hydroxytryptamine receptor 7
Molecular Weight
53554.43 Da
References
  1. Lucchelli A, Santagostino-Barbone MG, D'Agostino G, Masoero E, Tonini M: The interaction of antidepressant drugs with enteric 5-HT7 receptors. Naunyn Schmiedebergs Arch Pharmacol. 2000 Sep;362(3):284-9. [PubMed:10997731]
  2. Roth BL: Multiple serotonin receptors: clinical and experimental aspects. Ann Clin Psychiatry. 1994 Jun;6(2):67-78. [PubMed:7804391]
Kind
Protein group
Organism
Human
Pharmacological action
Unknown
Actions
Binder
General Function
G-protein coupled amine receptor activity
Specific Function
Dopamine receptor whose activity is mediated by G proteins which activate adenylyl cyclase.

Components:
References
  1. Toll L, Berzetei-Gurske IP, Polgar WE, Brandt SR, Adapa ID, Rodriguez L, Schwartz RW, Haggart D, O'Brien A, White A, Kennedy JM, Craymer K, Farrington L, Auh JS: Standard binding and functional assays related to medications development division testing for potential cocaine and opiate narcotic treatment medications. NIDA Res Monogr. 1998 Mar;178:440-66. [PubMed:9686407]
Details
18. D(2) dopamine receptor
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Binder
General Function
Potassium channel regulator activity
Specific Function
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase.
Gene Name
DRD2
Uniprot ID
P14416
Uniprot Name
D(2) dopamine receptor
Molecular Weight
50618.91 Da
References
  1. Peddi S, Roth BL, Glennon RA, Westkaemper RB: Structural determinants for high 5-HT(2A) receptor affinity of spiro[9,10-dihydroanthracene]-9,3(')-pyrrolidine (SpAMDA). Bioorg Med Chem Lett. 2004 May 3;14(9):2279-83. [PubMed:15081025]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarization
Specific Function
Pore-forming (alpha) subunit of voltage-gated inwardly rectifying potassium channel. Channel properties are modulated by cAMP and subunit assembly. Mediates the rapidly activating component of the ...
Gene Name
KCNH2
Uniprot ID
Q12809
Uniprot Name
Potassium voltage-gated channel subfamily H member 2
Molecular Weight
126653.52 Da
References
  1. Teschemacher AG, Seward EP, Hancox JC, Witchel HJ: Inhibition of the current of heterologously expressed HERG potassium channels by imipramine and amitriptyline. Br J Pharmacol. 1999 Sep;128(2):479-85. [PubMed:10510461]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Monoamine transmembrane transporter activity
Specific Function
Amine transporter. Terminates the action of dopamine by its high affinity sodium-dependent reuptake into presynaptic terminals.
Gene Name
SLC6A3
Uniprot ID
Q01959
Uniprot Name
Sodium-dependent dopamine transporter
Molecular Weight
68494.255 Da
References
  1. Melikian HE, Buckley KM: Membrane trafficking regulates the activity of the human dopamine transporter. J Neurosci. 1999 Sep 15;19(18):7699-710. [PubMed:10479674]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Activator
General Function
Serotonin receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances. Ligand binding causes a conformation change that triggers...
Gene Name
HTR1A
Uniprot ID
P08908
Uniprot Name
5-hydroxytryptamine receptor 1A
Molecular Weight
46106.335 Da
References
  1. Haddjeri N, Blier P, de Montigny C: Long-term antidepressant treatments result in a tonic activation of forebrain 5-HT1A receptors. J Neurosci. 1998 Dec 1;18(23):10150-6. [PubMed:9822768]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Binder
General Function
Serotonin receptor activity
Specific Function
This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. The activity of this receptor ...
Gene Name
HTR6
Uniprot ID
P50406
Uniprot Name
5-hydroxytryptamine receptor 6
Molecular Weight
46953.625 Da
References
  1. Grimaldi B, Bonnin A, Fillion MP, Ruat M, Traiffort E, Fillion G: Characterization of 5-ht6 receptor and expression of 5-ht6 mRNA in the rat brain during ontogenetic development. Naunyn Schmiedebergs Arch Pharmacol. 1998 Apr;357(4):393-400. [PubMed:9606024]
  2. Roth BL: Multiple serotonin receptors: clinical and experimental aspects. Ann Clin Psychiatry. 1994 Jun;6(2):67-78. [PubMed:7804391]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Phosphorelay sensor kinase activity
Specific Function
Pore-forming (alpha) subunit of a voltage-gated delayed rectifier potassium channel (PubMed:22732247). Channel properties may be modulated by subunit assembly, but not by cyclic nucleotides (By sim...
Gene Name
KCNH1
Uniprot ID
O95259
Uniprot Name
Potassium voltage-gated channel subfamily H member 1
Molecular Weight
111421.76 Da
References
  1. Garcia-Ferreiro RE, Kerschensteiner D, Major F, Monje F, Stuhmer W, Pardo LA: Mechanism of block of hEag1 K+ channels by imipramine and astemizole. J Gen Physiol. 2004 Oct;124(4):301-17. Epub 2004 Sep 13. [PubMed:15365094]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Not Available
Specific Function
Functions as transport protein in the blood stream. Binds various hydrophobic ligands in the interior of its beta-barrel domain. Also binds synthetic drugs and influences their distribution and ava...
Gene Name
ORM2
Uniprot ID
P19652
Uniprot Name
Alpha-1-acid glycoprotein 2
Molecular Weight
23602.43 Da
References
  1. Herve F, Duche JC, d'Athis P, Marche C, Barre J, Tillement JP: Binding of disopyramide, methadone, dipyridamole, chlorpromazine, lignocaine and progesterone to the two main genetic variants of human alpha 1-acid glycoprotein: evidence for drug-binding differences between the variants and for the presence of two separate drug-binding sites on alpha 1-acid glycoprotein. Pharmacogenetics. 1996 Oct;6(5):403-15. [PubMed:8946472]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  2. Koyama E, Chiba K, Tani M, Ishizaki T: Reappraisal of human CYP isoforms involved in imipramine N-demethylation and 2-hydroxylation: a study using microsomes obtained from putative extensive and poor metabolizers of S-mephenytoin and eleven recombinant human CYPs. J Pharmacol Exp Ther. 1997 Jun;281(3):1199-210. [PubMed:9190854]
  3. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and im...
Gene Name
CYP2C19
Uniprot ID
P33261
Uniprot Name
Cytochrome P450 2C19
Molecular Weight
55930.545 Da
References
  1. Shin JG, Park JY, Kim MJ, Shon JH, Yoon YR, Cha IJ, Lee SS, Oh SW, Kim SW, Flockhart DA: Inhibitory effects of tricyclic antidepressants (TCAs) on human cytochrome P450 enzymes in vitro: mechanism of drug interaction between TCAs and phenytoin. Drug Metab Dispos. 2002 Oct;30(10):1102-7. [PubMed:12228186]
  2. Morinobu S, Tanaka T, Kawakatsu S, Totsuka S, Koyama E, Chiba K, Ishizaki T, Kubota T: Effects of genetic defects in the CYP2C19 gene on the N-demethylation of imipramine, and clinical outcome of imipramine therapy. Psychiatry Clin Neurosci. 1997 Aug;51(4):253-7. [PubMed:9316174]
  3. Madsen H, Rasmussen BB, Brosen K: Imipramine demethylation in vivo: impact of CYP1A2, CYP2C19, and CYP3A4. Clin Pharmacol Ther. 1997 Mar;61(3):319-24. [PubMed:9084457]
  4. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  5. Koyama E, Chiba K, Tani M, Ishizaki T: Reappraisal of human CYP isoforms involved in imipramine N-demethylation and 2-hydroxylation: a study using microsomes obtained from putative extensive and poor metabolizers of S-mephenytoin and eleven recombinant human CYPs. J Pharmacol Exp Ther. 1997 Jun;281(3):1199-210. [PubMed:9190854]
  6. Obach RS, Reed-Hagen AE: Measurement of Michaelis constants for cytochrome P450-mediated biotransformation reactions using a substrate depletion approach. Drug Metab Dispos. 2002 Jul;30(7):831-7. [PubMed:12065442]
  7. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A2
Uniprot ID
P05177
Uniprot Name
Cytochrome P450 1A2
Molecular Weight
58293.76 Da
References
  1. Brosen K: Drug interactions and the cytochrome P450 system. The role of cytochrome P450 1A2. Clin Pharmacokinet. 1995;29 Suppl 1:20-5. [PubMed:8846619]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  3. Koyama E, Chiba K, Tani M, Ishizaki T: Reappraisal of human CYP isoforms involved in imipramine N-demethylation and 2-hydroxylation: a study using microsomes obtained from putative extensive and poor metabolizers of S-mephenytoin and eleven recombinant human CYPs. J Pharmacol Exp Ther. 1997 Jun;281(3):1199-210. [PubMed:9190854]
  4. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  2. Koyama E, Chiba K, Tani M, Ishizaki T: Reappraisal of human CYP isoforms involved in imipramine N-demethylation and 2-hydroxylation: a study using microsomes obtained from putative extensive and poor metabolizers of S-mephenytoin and eleven recombinant human CYPs. J Pharmacol Exp Ther. 1997 Jun;281(3):1199-210. [PubMed:9190854]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A7
Uniprot ID
P24462
Uniprot Name
Cytochrome P450 3A7
Molecular Weight
57525.03 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2B6
Uniprot ID
P20813
Uniprot Name
Cytochrome P450 2B6
Molecular Weight
56277.81 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C18
Uniprot ID
P33260
Uniprot Name
Cytochrome P450 2C18
Molecular Weight
55710.075 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Metabolizes several precarcinogens, drugs, and solvents to reactive metabolites. Inactivates a number of drugs and xenobiotics and also bioactivates many xenobiotic substrates to their hepatotoxic ...
Gene Name
CYP2E1
Uniprot ID
P05181
Uniprot Name
Cytochrome P450 2E1
Molecular Weight
56848.42 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
No
General Function
Not Available
Specific Function
Functions as transport protein in the blood stream. Binds various ligands in the interior of its beta-barrel domain. Also binds synthetic drugs and influences their distribution and availability in...
Gene Name
ORM1
Uniprot ID
P02763
Uniprot Name
Alpha-1-acid glycoprotein 1
Molecular Weight
23511.38 Da
References
  1. Ferry DG, Caplan NB, Cubeddu LX: Interaction between antidepressants and alpha 1-adrenergic receptor antagonists on the binding to alpha 1-acid glycoprotein. J Pharm Sci. 1986 Feb;75(2):146-9. [PubMed:2870173]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Toxic substance binding
Specific Function
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloid...
Gene Name
ALB
Uniprot ID
P02768
Uniprot Name
Serum albumin
Molecular Weight
69365.94 Da
References
  1. Yoo MJ, Hage DS: Use of peak decay analysis and affinity microcolumns containing silica monoliths for rapid determination of drug-protein dissociation rates. J Chromatogr A. 2011 Apr 15;1218(15):2072-8. doi: 10.1016/j.chroma.2010.09.070. Epub 2010 Oct 16. [PubMed:20956006]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Secondary active organic cation transmembrane transporter activity
Specific Function
Translocates a broad array of organic cations with various structures and molecular weights including the model compounds 1-methyl-4-phenylpyridinium (MPP), tetraethylammonium (TEA), N-1-methylnico...
Gene Name
SLC22A1
Uniprot ID
O15245
Uniprot Name
Solute carrier family 22 member 1
Molecular Weight
61153.345 Da
References
  1. Urakami Y, Okuda M, Masuda S, Akazawa M, Saito H, Inui K: Distinct characteristics of organic cation transporters, OCT1 and OCT2, in the basolateral membrane of renal tubules. Pharm Res. 2001 Nov;18(11):1528-34. [PubMed:11758759]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. Mahar Doan KM, Humphreys JE, Webster LO, Wring SA, Shampine LJ, Serabjit-Singh CJ, Adkison KK, Polli JW: Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. J Pharmacol Exp Ther. 2002 Dec;303(3):1029-37. [PubMed:12438524]
  2. Nagy H, Goda K, Fenyvesi F, Bacso Z, Szilasi M, Kappelmayer J, Lustyik G, Cianfriglia M, Szabo G Jr: Distinct groups of multidrug resistance modulating agents are distinguished by competition of P-glycoprotein-specific antibodies. Biochem Biophys Res Commun. 2004 Mar 19;315(4):942-9. [PubMed:14985103]
  3. Faassen F, Vogel G, Spanings H, Vromans H: Caco-2 permeability, P-glycoprotein transport ratios and brain penetration of heterocyclic drugs. Int J Pharm. 2003 Sep 16;263(1-2):113-22. [PubMed:12954186]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Quaternary ammonium group transmembrane transporter activity
Specific Function
Mediates tubular uptake of organic compounds from circulation. Mediates the influx of agmatine, dopamine, noradrenaline (norepinephrine), serotonin, choline, famotidine, ranitidine, histamin, creat...
Gene Name
SLC22A2
Uniprot ID
O15244
Uniprot Name
Solute carrier family 22 member 2
Molecular Weight
62579.99 Da
References
  1. Urakami Y, Akazawa M, Saito H, Okuda M, Inui K: cDNA cloning, functional characterization, and tissue distribution of an alternatively spliced variant of organic cation transporter hOCT2 predominantly expressed in the human kidney. J Am Soc Nephrol. 2002 Jul;13(7):1703-10. [PubMed:12089365]
  2. Urakami Y, Okuda M, Masuda S, Akazawa M, Saito H, Inui K: Distinct characteristics of organic cation transporters, OCT1 and OCT2, in the basolateral membrane of renal tubules. Pharm Res. 2001 Nov;18(11):1528-34. [PubMed:11758759]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Toxin transporter activity
Specific Function
Mediates potential-dependent transport of a variety of organic cations. May play a significant role in the disposition of cationic neurotoxins and neurotransmitters in the brain.
Gene Name
SLC22A3
Uniprot ID
O75751
Uniprot Name
Solute carrier family 22 member 3
Molecular Weight
61279.485 Da
References
  1. Wu X, Huang W, Ganapathy ME, Wang H, Kekuda R, Conway SJ, Leibach FH, Ganapathy V: Structure, function, and regional distribution of the organic cation transporter OCT3 in the kidney. Am J Physiol Renal Physiol. 2000 Sep;279(3):F449-58. [PubMed:10966924]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Symporter activity
Specific Function
Sodium-ion dependent, low affinity carnitine transporter. Probably transports one sodium ion with one molecule of carnitine. Also transports organic cations such as tetraethylammonium (TEA) without...
Gene Name
SLC22A4
Uniprot ID
Q9H015
Uniprot Name
Solute carrier family 22 member 4
Molecular Weight
62154.48 Da
References
  1. Wu X, George RL, Huang W, Wang H, Conway SJ, Leibach FH, Ganapathy V: Structural and functional characteristics and tissue distribution pattern of rat OCTN1, an organic cation transporter, cloned from placenta. Biochim Biophys Acta. 2000 Jun 1;1466(1-2):315-27. [PubMed:10825452]

Drug created on June 13, 2005 07:24 / Updated on December 10, 2017 17:18